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 Neural recording devices are a therapeutic and diagnostic option for central nervous 
system (CNS) diseases and a vital component of neuroscience research.  However, poor 
functional longevity is a major hurdle facing this broad class of devices.  Decreases in 
functionality are associated, in part, with the foreign body response (FBR) surrounding chronically 
implanted recording devices; which includes chronic inflammation, astrogliosis, blood-brain 
barrier (BBB) leakiness, and neuronal cell death.  Two potential areas for intervention were 
explored including the initial hemorrhage that results from device insertion and the 
neuroinflammatory sequela.  Researchers have shown that cellular interactions with extracellular 
matrix (ECM) are able to affect both of these aspects of the FBR.  The central hypothesis driving 
this work is that ECM coatings which target the initial hemorrhage, should decrease the FBR.  
This was investigated by coating silicon microelectrode arrays (MEAs) with ECM and implanting 
them into motor cortex of rats.  Two ECM coatings were investigated, including the xenogeneic 
clinically-used Avitene Microfibrillar Collagen Hemostat and allogeneic astrocyte-derived ECM.  
Results show that the allogeneic astrocyte-derived ECM decreased astrogliosis within the 
recording zone at the 8-week time point.  This decrease in astrogliosis may improve device 
functionality, as indicated by previous studies that correlated recording metrics to histology.  
Interestingly, the xenogeneic Avitene coating increased IgG within the recording zone at the 8-
week time point.  Collectively, these results show that ECM coatings with different genetic 
backgrounds and compositions are able to differentially affect specific aspects of the FBR.  To 
broaden the knowledge on the FBR to neural recording devices, the FBR of headstage 
components used to anchor CNS devices to the skull was analyzed.  Results showed that the 
FBR to fixation screws and fixation anchoring adhesive illicit a chronic FBR that has all of the 
hallmarks described for MEAs implanted in brain tissue.  Moreover, results show evidence of 
persistent neuroinflammation below a variety of fixation screws including chronic macrophage 
 iv 
activation, demyelination, and neural tissue loss.  Understanding the FBR of fixation techniques, 
which is common to a wide variety of CNS devices, may improve the biocompatibility of existing 
devices and provide a reference for future biologically-informed device designs. 
  





ABSTRACT ...................................................................................................................................... iii 
 
LIST OF FIGURES ........................................................................................................................ viii 
 
LIST OF ABBREVIATIONS .............................................................................................................. x 
 




1 INTRODUCTION ........................................................................................................................ 1 
 
 1.1 CNS Diseases and Injuries..................................................................................... 1 
 1.2 Therapeutic Implants for CNS Diseases and Injuries ............................................ 4 
 1.3 Limitations and Concerns of Current and Investigational Devices ......................... 8 
 1.4 The Foreign Body Response to Implanted Devices ............................................. 11 
 1.5 Previous Efforts to Minimize the Tissue Response to CNS Implants................... 17 
 1.6 Hemorrhage and Hemostasis in the CNS:  Background for Hemostatic ECM 
Coatings................................................................................................................ 20 
 1.7 The Role of ECM in Immunomodulation and CNS Wound Healing:  Background 
for Immunomodulatory ECM Coatings ................................................................. 21 
 1.8 Fixation and Neuroinflammation of Chronic CNS Devices:  Background for 
Headstage FBR Analysis ...................................................................................... 22 
 1.9 Introduction to This Dissertation ........................................................................... 24 
 
2 A COMPARISON OF THE BRAIN TISSUE FBR TO ECM PROTEIN COATED AND 
UNCOATED SILICON MICROELECTRODES ........................................................................ 32 
 
 2.1 Introduction ........................................................................................................... 32 
 2.2 Methods ................................................................................................................ 33 
 2.3 Results .................................................................................................................. 42 
 2.4 Discussion ............................................................................................................ 44 
 2.5 Conclusion ............................................................................................................ 48 
 
3 THE FOREIGN BODY RESPONSE TO HEADSTAGE COMPONENTS USED FOR DEVICE 
FIXATION IN CHRONIC CNS STUDIES IN RATS ................................................................. 59 
 
 3.1 Introduction ........................................................................................................... 59 
 3.2 Methods ................................................................................................................ 60 
 3.3 Results .................................................................................................................. 64 
 3.4 Discussion ............................................................................................................ 65 
 3.5 Conclusion ............................................................................................................ 69 
 
4 CONCLUSIONS AND FUTURE WORK .................................................................................. 76 
 




 4.2 Future Directions and Approaches ....................................................................... 78 
 







1.1 Vasculature of the rodent brain ......................................................................................... 27 
 
1.2 Stereotypical foreign body response in the rodent brain ................................................... 28 
 
1.3 Acute hemorrhagic response to cortically implanted MEAs .............................................. 29 
 
1.4 Chronic fixation of a recording various experimental CNS devices .................................. 30 
 
1.5 Screw types commonly used for device fixation to rodent skull ........................................ 31 
 
2.1 Cell-derived biomaterial process schematic ...................................................................... 49 
 
2.2 Rat cortical implantation schematic ................................................................................... 49 
 
2.3 Avitene MCH dry macroscopic appearance, suspension, and TEM characterization ...... 50 
 
2.4 Astrocyte-derived ECM scaffold and immunolabeled proteins .......................................... 50 
 
2.5 In vitro hemostatic and immunomodulatory characterization of ECM ............................... 51 
 
2.6 Dip coating apparatus with astrocyte-derived ECM and Avitene coated MEAs ................ 52 
 
2.7 Representative images of in vivo GFAP immunoreactivity and quantification .................. 53 
 
2.8 Representative GFAP immunoreactivity at high magnification ......................................... 54 
 
2.9 Representative images of in vivo IgG immunoreactivity and quantification ...................... 55 
 
2.10 Representative images of in vivo CD68 immunoreactivity and quantification ................... 56 
 
2.11 Representative images of in vivo NeuN immunoreactivity and quantification ................... 57 
 
3.1 MEA headstage and self-tapping fixation screw skull penetration .................................... 70 
 
3.2 Explanted device immunohistological surface analysis .................................................... 70 
 
3.3 Immunohistological surface analysis of blunt machine screw ........................................... 71 
 
3.4 Macroscopic remodeling of the cortex adjacent to fixation screws ................................... 72 
 
3.5 Immunolabeling of inflammatory biomarkers in cortical tissue 
 adjacent to screw location (coronal plane) ........................................................................ 73 
 
3.6 Astrogliosis in cortical tissue adjacent to screw location (coronal plane) 
 and upregulation of inflammatory biomarkers (horizontal plane) ...................................... 74 
 ix 
3.7 Loss of cytoarchitectural and neurovascular networks (NeuN, NF200, RIP and TL) 
 in cortical tissue adjacent to screw position (horizontal) ................................................... 75 
 
3.8 Drawing comparing self-tapping bone screw dimensions with 
 skull thickness of young and old adult rats ........................................................................ 75 
 
4.1 Surface adherent macrophages on single-shank and multi-shank MEAs ........................ 89 
 
4.2 Electrospun polyurethane scaffolds and astrocyte-derived ECM cell sheet ..................... 90 
 
4.3 Single-shank lattice geometry silicon MEA coated with astrocyte-derived ECM .............. 90 
 
4.4 Lesion size at various cortical depths resulting from multi-shank MEA implantation ........ 91 
 
4.5 Theoretical titanium headstage mount for fixation of electrical connector in rodents ....... 92 
 








ALS ..................................................................................................... Amyotrophic Lateral Sclerosis 
 
BBB ...................................................................................................................... Blood Brain Barrier 
 
CD-68 .......................................................... Pan Macrophage Marker (Center of Differentiation-68) 
 
CNS ............................................................................................................ Central Nervous System 
 
CSF ................................................................................................................... Cerebral Spinal Fluid 
 
DBS ............................................................................................................... Deep Brain Stimulation 
 
DMAC .................................................................................................................. Dimethylacetamide 
 
DARPA .................................................................... Defense Advanced Research Projects Agency 
 
ECM ..................................................................................................................... Extracellular Matrix 
 
FBGC ........................................................................................................... Foreign Body Giant Cell 
 
FBR .............................................................................................................. Foreign Body Response 
 
FDA .....................................................................................................Food and Drug Administration 
 
GFAP ..................................................................................................... Glial Fibrillary Acidic Protein 
 
IBA-1 ............................................................................ Ionized Calcium Binding Adaptor Molecule 1 
 
NDD ....................................................................................................... Neurodegenerative Disease 
 
NIH ......................................................................................................... National Institutes of Health 
 
MEA .................................................................................................................. Microelectrode Array 
 
MS ......................................................................................................................... Multiple Sclerosis 
 
PD ........................................................................................................................ Parkinson Disease 
 
PU ................................................................................................................................. Polyurethane 
 
SCI ......................................................................................................................... Spinal Cord Injury 
 
TBI .................................................................................................................. Traumatic Brian Injury 
 
TGFβ1 .............................................................................................. Transforming Growth Factor β1 
 xi 
TNF-α ................................................................................................ Tumor Necrosis Factor – alpha 
 





 I would like to sincerely thank my advisor and mentor, Dr. Patrick Tresco, who offered me 
a research position in the summer of 2011.  His mentorship has strengthened many facets of my 
professional development, especially my scientific approach as a research assistant and 
educational approach as a teaching assistant.  I also want to acknowledge my advisory 
committee members:  Drs. Chuck Dorval, David Grainger, Vladimir Hlady, and Paul House for 
their mentorship in regards to my projects as well as in the classroom and various department 
events.  I would like to thank other members of the Tresco Lab for their support and 
companionship during my studies including Dr. Elena Budko, Dr. Ben Christiansen, Dr. John 
Skousen, Dr. Fan-Wei Meng, Nick Nolta, Michael Polei, and Bharath Velagapudi as well as the 
many other undergraduates and high school students who have come through the lab as 
volunteers.  I would like to thank Defense Advanced Research Projects Agency and the National 
Institutes of Health for funding parts of my research through grants N66001-11-1-4120 / N66001-
12-C-4002 and 5R21NS088737-02, respectively.  I would like to thank the University of Utah’s 
Department of Bioengineering and previous chair Dr. Rick Rabbitt and present chair Dr. Patrick A. 
Tresco for facilitating my teaching assistantships throughout my graduate student career.  Along 
with the teaching assistantships, I would like to thank the wonderful students whom I instructed in 
Fundamentals of Bioengineering and Introduction to Modern Biomaterials, both were great 
teaching as well as learning experiences.  Thanks to Troy D’Ambrosio who gave me the 
opportunity to work at the Lassonde New Venture Development Center where I was able to 
improve communication and personal management skills. 
 I would like to thank all of the members of my family.  Special thanks to my parents, 
Marty and Toni, who have always supported my pursuits both academically and personally.  They 
are the greatest teachers I have ever had, in the most important subject of all, life.  I especially 
want to express my appreciation for my best friend and wife, Amelia, who encourages and 
 xiii 
inspires me.  As both of us are graduate students, many of our date nights included homework 
and paper writing, with the occasional email proofread.  Lastly, I want to thank my late brother 
Sam for being my inspiration to pursue a career with an emphasis on improving the lives of 
others.  He always saw the best in people and made every effort to help those in need, whether 









 This introduction establishes the background necessary to understand the studies that 
follow including a discussion of the pathogenesis and prevalence of central nervous system 
(CNS) injuries and diseases, their treatment with chronically implanted devices, the limitations 
and concerns associated with those devices with a special focus on the foreign body response 
(FBR), and previous efforts to mitigate the FBR in brain tissue.  Special emphasis is placed on 
silicon microelectrode arrays (MEAs) as this was the model system used in the experimental 
aspects of the dissertation.  This also included associated components used to anchor such 
device to the skull, hemorrhage in the brain due to device implantation, immunomodulatory 
potential of ECM, and the influence of neuroinflammation on global brain function.  Finally, 
section 1.9 introduces the rationale, hypotheses, and results for this dissertation as a whole. 
 
1.1  CNS Diseases and Injuries 
 Diseases and injuries to the CNS, which includes the brain and spinal cord, are currently 
some of the most debilitating conditions for patients and healthcare systems as a whole.  Due to 
the wide array of CNS diseases and injuries, an accurate measure of the collective prevalence 
and economic burden is not available.  However, some of the most common diseases and 
injuries are detailed below to establish a point of reference for the impact of the experimental 
work that follows. 
 
1.1.1  Neurodegenerative diseases 
 Neurodegenerative diseases (NDD) make up a large subset of CNS diseases, especially 
in the elderly population.  Alzheimer disease is the most common NDD and cause of dementia in 
the United States (US).  Alzheimer disease results from plaques and neurofibrillary tangles, that 
 2 
 
are similar to implanted devices or foreign bodies, in the cerebral cortex which are associated 
with synaptic dysfunction, neuronal degeneration, and progressive cognitive decline [1].  In 2015, 
the prevalence of Alzheimer disease in the US was approximately 5.1 million people and the 
estimated economic burden (health care, long-term care, hospice) is expected to reach $226 
billion for Alzheimer disease and other types of dementia [2].  Parkinson disease is the second 
most common NDD.  Parkinson disease results from the death of dopamine-producing neurons in 
the pars compacta of the substantia nigra [3].  The symptoms are characterized by the unilateral 
onset of resting tremor in combination with varying degrees of rigidity and bradykinesia.  As of 
2010, the prevalence of Parkinson disease is approximately 630,000 people in the US with a 
projected economic burden exceeding $14.4 billion [4].  Lastly, a third NDD which is less 
prevalent but has a profound effect on the health individuals is amyotrophic lateral sclerosis 
(ALS), also known as Lou Gehrig Disease.  ALS results from axonal denervation and neuronal 
cell death in lower motor neurons in the brainstem and spinal cord as well as the upper motor 
neurons in the motor cortex.  This leads to muscle atrophy and weakness, fasciculations, and 
spasticity [5].  In 2012, there were 12,187 individuals identified as suffering from ALS in the US 
with a majority of individuals dying within 2-5 years following symptom onset [6].  The prevalence 
and economic burden of all NDDs is expected to scale with the ever-increasing elderly 
population, which is compounded by the baby boomer population who will all be 65 years of age 
or older by 2029 (approximately 20% of the total US population) [7]. 
 
1.1.2  Hydrocephalus 
 Hydrocephalus is a disease that most often affects infants and children.  It is defined as 
an active distension of the ventricular system of the brain resulting from inadequate passage of 
cerebrospinal fluid (CSF) from its point of production within the cerebral ventricles to its point of 
absorption into the systemic circulation [8].  The consequence of this inadequate passage in 
infants is often an increase in head circumference that is accompanied by severe cognitive or 
motor dysfunction.  Hydrocephalus may also develop in adults following brain injury.  The 
prevalence of hydrocephalus has not been regularly assessed, however, one report estimates 
that there were 39,904 pediatric hospital admissions related to hydrocephalus based on data in 
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2003, which accounted for healthcare costs of approximately $2 billion [9]. 
 
1.1.3  Stroke and aneurysm 
 Stroke is the leading cause of long-term CNS-related disability in the US.  A stroke is a 
disruption of the vasculature and the subsequent lack of perfusion in downstream brain tissue, 
which leads to a loss of neural tissue and its associated function.  The two forms of stroke include 
ischemic, caused by arterial obstruction, and hemorrhagic, caused by vascular rupture.  As of 
2015, approximately 6.6 million people over 20 years of age have had a stroke in the US.  In 
2013, the estimated direct and indirect cost of stroke was $33.6 billion [10].  Analogous concerns 
to hemorrhagic stroke are brain aneurysms.  An aneurysm is a ballooning or bulging of 
vasculature and can potentially lead to a hemorrhagic stroke, however, a majority do not rupture.  
Between 2002 and 2010, there were 54,589 admissions for unruptured intracerebral aneurysms 
[11]. 
 
1.1.4  Traumatic brain injury and spinal cord injury 
 Traumatic brain injury (TBI) occurs when any external force creates damage to brain 
tissue or causes neural dysfunction.  The most common cause of TBI is motor vehicle accidents.  
Due to the varying levels of TBI (mild, moderate, and severe), there are a wide range of physical 
and psychological symptoms.  As of 2005, the estimated prevalence of TBI was 3.32 million 
people in the US and the estimated economic burden of TBI in 2013 was approximately $78.1 
billion [12].  Spinal cord injury (SCI) is another form of injury to the CNS, specific to the spinal 
cord.  Similar to TBI, the most common cause of SCI is motor vehicle accidents [13].  Individuals 
with SCI experience a partial or complete loss of motor function in lower extremities depending on 
the location of the injury.  In 2012, the estimated prevalence of SCI was 236,000-327,000, with an 
associated economic burden of $9.7 billion [12]. 
 All indices of prevalence and economic burden presented in this section were based on 
estimates available in literature.  It should be noted that these examples are not exhaustive and 
estimates of prevalence and economic burden vary between various academic studies as well as 
dedicated health organizations, which may use different methods for reaching their estimates. 
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1.2  Therapeutic Implants for CNS Diseases and Injuries 
 A number of therapeutic strategies have been developed to address the diseases and 
injuries listed in section 1.1.  One of the most common strategies, along with pharmaceutical 
intervention, is medical device implantation.  The medical devices detailed below range from 
clinically utilized to investigational. 
 
1.2.1  Deep brain stimulators 
 Deep brain stimulators (DBS) are a successful therapeutic brain implanted device, which 
become particularly beneficial for patients that suffer from Parkinson disease and essential tremor 
where it is able to significantly decrease tremor severity.  DBS has been beneficial for modulating 
several other neurological conditions including pain, epilepsy, addiction, and depression [14-16].  
The device includes an implantable pulse generator and stimulating electrode array consisting of 
several platinum-iridium contacts [17].  This electrode is considered a macroelectrode given its 
size (0.06 cm2).  Experimental findings from Magariños-Ascone et al. suggest that the therapeutic 
benefit for Parkinson disease is a result of DBS’ high frequency stimulation suppressing the 
action potentials of subthalamic neurons [18].  However, the specific mechanisms of action for 
DBS are still poorly understood.  Regardless, the clinical benefit has overshadowed these 
unknowns and led to DBS’ increasing adoption as a therapeutic device, with the DBS market 
projected to increase yearly at 8.9% (compound annually) between 2014 and 2020 [19]. 
 
1.2.2  Cell encapsulation and drug elution implants 
 Another device which has been proposed as a therapeutic for Parkinson disease is 
cellular encapsulation devices.  In one set of studies, encapsulated dopamine-secreting PC12 
cells were able to elicit functional recovery in Parkinsonian rats (6-OHDA hydrobromide lesion in 
substantia nigra) as determined by quantification of rotational behavior [20, 21].  The cell 
encapsulation approach has been postulated for a large variety of CNS diseases, with some 
approaches reaching clinical trials.  However, while clinical trials have shown that cell 
encapsulation devices are relatively safe, their clinical progress has been hindered due to low 
efficacy [22].  Along the same lines as cell encapsulation devices, drug releasing implants also 
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aim to modulate the neural environment with various soluble factors, and have been investigated 
for NDDs and brain cancer [23, 24].  One of the most clinically successful examples are 
carmustine wafers (bis-chloroethylnitrosourea, Gliadel®) used in the treatment of patients with 
malignant gliomas and other intracranial malignancies [24]. 
 
1.2.3  Hydrocephalic shunts 
 Shunts, or intraventricular catheters, have proven efficacious for the treatment of 
hydrocephalus.  Alleviation of elevated CSF pressure is achieved through a silicon elastomer 
catheter implanted in the ventricular space and draining into the peritoneal cavity.  The passage 
of CSF is controlled with an inline siphon-preventing backflow, or a flow control device, which has 
seen a considerable amount of development over the past two decades.  The most notable 
design improvement is the advent of adjustable pressure valves which can be set following 
implantation [25]. 
 
1.2.4  Aneurysm clips and endovascular coils 
 Aneurysm clips or endovascular coils are the two device options for individuals who have 
a ruptured aneurysm.  This clipping or coiling is intended to limit the risk of a subsequent rupture 
and hemorrhage.  Clips are typically made of titanium whereas the detachable coils are mostly 
platinum.  Some newer coil designs are integrating polymers and thrombogenic agents to 
promote clotting inside the aneurysm [26, 27].  Coiling is the most recently developed of the two 
options and has shown better outcomes in comparison to surgical clipping.  In a clinical study, 
which focused on subarachnoid hemorrhage as a result of aneurysm, coiling significantly 
decreased the risk of re-hemorrhage as compared to clipping [28].  Another major advantage of 
coiling is that a craniotomy is not required which improves patient recovery time. 
 
1.2.5  Microelectrode arrays 
 Microelectrode arrays (MEAs) are used for high resolution stimulation and recording from 
neuronal cell bodies or cell clusters.  They are an emerging technology used in the treatment of 
NDDs, Stroke, TBI, and SCI [16].  The most powerful form of stimulation and recording occurs at 
the cellular level.  Specific to recording, single-unit action potentials (APs) acquired from 
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intracortical microelectrodes provide the highest neural signal resolution.  Other modes of 
recording including electroencephalography (EEG), electrocorticography (ECoG), and local field 
potentials (LFP) have many potential benefits and have been reviewed extensively [29-32].  
However, unlike the intracortical microelectrodes needed for single-unit APs, the requisite devices 
for these other modalities do not penetrate brain tissue.  Additionally, these other modalities have 
a lower potential for recording resolution and do not experience the same in vivo complications as 
intracortical microelectrodes.  For these reasons, devices that do not penetrate the brain are not a 
focus of this dissertation.  For measuring single-unit APs the most common devices are 
microwires or microfabricated silicon microelectrode arrays. 
 Microwires are historically the most utilized device for single-unit AP recordings [29].  To 
the best of my knowledge, their use currently is limited to neurophysiology research.  These wires 
are commonly 30-50 μm in diameter (after insulation) with the electrical conduit being a pure 
metal (tungsten or gold) or an alloy (stainless steel or platinum/iridium).  Typical materials used to 
electrically insulate the wire include polyimide, poly-para-xylylene (Parylene), or 
polytetrafluoroethylene (Teflon) [33].  Some labs fabricate microwires into arrays in-house, which 
enables a high degree of customization and affordability.  The Nicolelis Lab (Duke University) 
detailed some of the advantages of customization such as contour mapping and specificity of tip 
geometry [34].  There are also a number of commercial options which have more recently allowed 
for higher levels of customization, with the added benefit of guaranteed device tolerances 
(electrode length, impedance, etc.).  An example is Tucker-Davis Technologies (Alachua, FL) 
who have a web applet that allows neurophysiology researchers to design custom microelectrode 
arrays [35]. 
 Microfabricated silicon MEAs are a commercially available neural recording device 
option.  The high cost, inaccessibility of equipment, and advanced techniques required for their 
fabrication restrict the in-house customization afforded to microwire arrays.  However, similar to 
commercial microwire arrays, highly customizable silicon arrays are available from manufacturers 
in two-dimensional and three-dimensional configurations. 
 Two-dimensional or planar silicon arrays are most associated with the University of 
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Michigan, where their development has been extensive and led to the company Neuro-Nexus.  
To the best of my knowledge, their use currently is limited to neurophysiology research.  These 
planar devices may be single or multishanked and are made through photolithography processes 
similar to semiconductors and microelectromechanical systems.  In brief, the microfabrication 
process begins with a silicon substrate which is boron-doped and etched (deep-reactive ion etch) 
to define the MEAs profile.  The processed silicon shank is then functionalized with metallic 
deposition of gold, platinum, or iridium oxide recording and stimulating sites depending on 
intended application.  The probe is then separated from the silicon wafer and the shanks are 
insulated via a low-pressure chemical vapor deposition.  Several organic materials have been 
investigated for final packaging including polyimide and Parylene.  All dimensions are 
lithographically controlled with tolerances well below 1 μm [36]. 
 Three-dimensional silicon arrays are most associated with the University of Utah, where 
their development has been extensive and are now marketed by the company Blackrock 
Technologies, Inc., located near the University of Utah.  To the best of my knowledge and 
according to the National Institutes of Health (NIH, clinicaltrials.gov) these are the only cortically 
implanted MEA approved by the Food and Drug Administration (FDA) for use in human clinical 
trials, with the patient condition limited to tetraplegia, spinal cord injury, and brainstem stroke.  
The microfabrication of the UEA is quite different in nature to the lithography methods used for 
the 2D MEAs.  First, a silicon block is processed via thermomitigation which dopes the silicon with 
aluminum creating tracts of highly conductive p+ silicon.  A micro-sawing technique followed by 
etching creates high aspect ratio individual shanks.  Each shank is electrically isolated from one 
another at the base as a result of the regionalized p+ silicon being encased in nonconductive n-
type silicon.  Each shank tip is then sputtered with iridium oxide (originally platinum was used) 
and insulated with Parylene-C (originally polyimide was used) [37].  This design of the UEA is 
roughly the same in 2015 as it was in 1990 when fabricated by Dr. Richard Normann’s lab [38, 
39].  Some of the most promising design modifications to the UEA are variable shank length 




 Sensory loss and limb amputation are two injuries not specific to CNS tissue but could 
benefit from stimulating and recording microelectrodes.  Individuals suffering from sensory loss 
could benefit from stimulation of a specific brain region, thus bypassing the defunct sensory cells 
or pathway [41].  Example diseases include blindness or deafness, which may result from injury 
or degeneration of peripheral sensory cells or pathway. 
 One disease that exemplifies this scenario is macular degeneration which results from 
degradation of the central portion of vision due to photoreceptor inhibition or death.  These 
photoreceptors are then unable to provide stimulation to brain’s visual cortex, which results in 
large scale reorganization of visual processing [42].  Macular degeneration is currently the 
leading cause of blindness in the developed world.  In addition, whole limb amputees could also 
benefit from recording MEAs implanted in the motor cortex, thus enabling control of high 
resolution robotic prostheses.  In 2006 Hochberg et al. provided the proof-of-principle 
experiments for human control of robotic apparatuses when a tetraplegic patient was able to 
control a computer mouse and robotic hand with a UEA implanted in motor cortex [43]. 
 
1.3  Limitations and Concerns of Current 
 
and Investigational Devices 
 
 Of the device classes discussed in section 1.2, all have limitations in efficacy or safety 
concerns [22, 44-49].  One broad concern is infection, as with all surgical procedures and 
implanted devices [50].  While infections are problematic everywhere in the body, they can be 
particularly difficult to treat in the brain.  One study looked at the effect of prophylaxis, an 
antibiotic, on patients with meningitis (infection of the tissue surrounding the brain).  Of the 6243 
patients with craniotomies (no device insertion), it was shown that prophylaxis did not significantly 
decrease meningitis, even though it significantly decreased the infection rate of the dermal 
incision site [51].  One way that hydrocephalic shunt technology has combated infection is with 
impregnated antibiotics, which have been shown to decrease the incidence of shunt-related 
infections [52].  While infection is a uniform concern for all devices, other device-specific concerns 
including intracortical hemorrhage, shunt occlusion, recording device reliability, and deep-brain 
stimulation efficacy, all contribute to poor functional longevity.  Two devices that have been 
 9 
 
especially troubled by poor functional longevity are hydrocephalic shunts in clinical use and 
cortically-implanted recording MEAs in research, which has inhibited their clinical use. 
 
1.3.1  Failure of hydrocephalic shunts 
 In a study on hydrocephalic shunts which tracked 64 patients, ages ranged from days old 
to adolescence, it was shown that 84.5% of patients required at least one shunt revision surgery 
and 4.7% of patients required 10 or more revision surgeries [53].  The most prevalent cause was 
catheter occlusion, which accounted for 42% of all failures.  Other common causes of failure were 
catheter disconnection (11%) and infection (9%).  More than half of shunt failures and revisions 
occur within the first year.  Following these acute failures, revisions were still required at time 
points beyond 15 years for some patients.  Of all the revisions, 65.5% required replacement of 
the brain implanted proximal catheter.  Proximal catheter occlusion occurs when tissue 
encapsulates the perforated catheter tip and invades the lumen of catheter through the drainage 
holes [54].  This tissue encapsulation and lumen infiltration is driven by various reactive cell types 
(inflammatory and glial) [45, 55]. 
 
1.3.2  Failure of recording microelectrode arrays 
 A majority of the knowledge about shunt failure has been obtained through clinical 
observations, explanted device analysis, and in vitro material analysis.  Conversely, the majority 
of knowledge about chronic recording MEA failure has been obtained from animal experiments.  
This results from the neuroscience communities’ extensive use of recording MEAs as a basic 
research tool.  To date they have only been used in a limited number of clinical trials, due to a 
lack of device reliability and longevity [56].  In various in vivo neural recording studies using 
various species (rat, guinea pig, cat, nonhuman primate, and human) all have shown that 
recording quality fluctuates unpredictably and decreases over time [49, 57-65]. 
 A retrospective study which exemplifies many of the concerns with recording MEAs was 
put together by the Donoghue group covering two decades of neural recording experiments in 
nonhuman primates (NHP).  It represents one of the most comprehensive failure analyses 
conducted to date in nonhuman primates [49].  The studies used the UEA described in section 
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1.2, with a common set of measures to evaluate recording performance failure.  Overall, 78 UEAs 
were implanted in 27 NHPs with failures grouped into acute or chronic and sorted based on 
failure type within the four categories which included material, mechanical, biological, and 
unknown mechanisms.  The mean recording duration was 387 days (range of 0 to 2104 days) 
with a majority of the recording failures occurring within the first year of implantation.  Acute 
mechanical failures were most prevalent at acute time points 48%, and macroscopic biological 
response (meningeal encapsulation) led to 53% of all chronic failures.  One aspect of the 
mechanical and material failures that was not considered in these categories was the influence of 
biological factors.  For instance, headstage loosening was grouped under mechanical failure, 
however, it was noted that a major factor of the failure was the tissue response to the headstage 
material.  Another example was the failure of insulating material, which may be influenced to the 
corrosive nature of physiological environment [66, 67].  An area of failure that was not extensively 
investigated in this study was those induced by tissue responses on the cellular level. 
 A recent study focused on the FBR as it relates to single unit recording quality and 
longevity using a 16-shank (4 x 4) UEA implanted in rats.  Results showed that a lesion/cavity 
formed below the implanted UEA, near the center of the implant. Single unit recording 
performance of microelectrodes in the center of the electrode array performed significantly worse 
than those located at the edge of the array.  The reduction of recording performance in the center 
of the UEA was associated with elevated FBR, astrogliosis, and blood-brain barrier (BBB) 
leakiness [68].  Lastly, given that applied sciences tend to outpace the progress of basic sciences 
(biology, physics, etc.), it is reasonable to believe that improvements in device design and 
manufacturing will limit mechanical and material failures, thus increasing the likelihood that 
biological failures will dominate in the future [69]. 
 While hydrocephalic shunts and recording MEAs have drastically different therapeutic 
applications, there are similarities between their failure modes.  First, the majority of failures for 
both occur within the first year following implantation.  Second, revision of the device usually 
requires removal or replacement.  Finally, a majority of failures for shunts (acute and chronic time 
points) and for MEAs (chronic time points) are attributed to the FBR.  Additionally, enhanced 
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astrocyte reactivity and cell attachment to the device is a common failure mode for both types of 
devices [45, 68].  For these reasons, understanding and reducing the FBR in brain tissue has 
been the primary focus of many studies seeking to improve the biocompatibility of this class of 
devices [70-77]. 
 
1.4  The Foreign Body Response to Implanted Devices 
 There are a number of differences in the CNS FBR compared to other tissues such as 
loose connective tissue or bone.  For brevity, this section will focus on the FBR to chronically 
implanted devices in brain tissue.  The relationship between the CNS and non-CNS tissue 
response has been detailed in several reviews [78, 79].  The tissue response in the CNS can be 
roughly classified into four phases:  hemostasis, inflammation, proliferation, and remodeling [78].  
The divisions between these phases are not stringently demarcated and it is important to 
recognize that the tissue response is a continuum.  The moment of injury is the first aspect of the 
response to consider as it leads to mechanical damage of cells and their resulting apoptosis, 
necrosis, or inflammatory activation.  Injury severity has influence on the scale of the four 
following phases [80, 81]. 
 
1.4.1  CNS hemostasis 
 Hemostasis is the first phase of the tissue response following injury or the implantation of 
a biomedical device.  It is the process of stopping the initial hemorrhage, which is facilitated 
through activation of the coagulation cascade and formation of a blood clot, in which platelets 
play crucial role.  The process of hemostasis begins immediately following breakage of 
vasculature, and can last for several hours depending on the severity of the insult.  Hemorrhage 
can be pronounced in brain tissue due to its dense vascularization and is accompanied by 
neuronal death caused by nutrient deprivation, activation of the complement cascade, activation 
of neutrophils, and macrophages [82, 83].  Dense vascularization, detailed in Fig. 1.1, is required 
to maintain the metabolic activity of neural tissue [84]. 
 The initial hemorrhage is the major complication in stroke, ruptured aneurysms, and 
traumatic brain injury.  For larger penetrating implants, DBS and shunts, vasculature networks are 
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approached with great caution during insertion due to the dangers of hemorrhage [85].  Few 
studies have examined the hemorrhage that results from the implantation of MEAs but it is 
commonly indicated as a concern [56, 86-89].  Given this dissertations focus, a more detailed 
background on hemorrhage and hemostasis is reviewed in section 1.6. 
 
1.4.2  Neuroinflammation 
 Following injury or the implantation of a biomedical device, inflammation is initiated during 
the process of hemostasis and continues for variable lengths of time depending on the severity of 
the injury or the indwelling period of the implant [90].  This process is directed by neutrophils 
initially, and then by macrophages, which are influenced by signaling molecules that result from 
cellular damage or from various phases of the hemostasis process (e.g., platelet degranulation) 
[91].  The first inflammatory cells to respond are neutrophils, which flood into the extracellular 
space during vessel rupture.  They are also recruited from the surrounding intact vasculature 
through binding to various intravascular adhesion receptors, activated following injury, and 
intravascular rolling that facilitates extravasation through the endothelial wall [92].  Neutrophils at 
the wound site release proteolytic enzymes and reactive oxygen species during the phagocytosis 
and degradation of damaged tissue or at the surface of the foreign body (biomedical device) [93].  
Following the initial influx of neutrophils, they undergo apoptosis after several days and are 
phagocytized by activated macrophages [94].  From that point on the inflammatory process is 
mostly dictated by extravasation of circulating monocytes, which then differentiate into 
macrophages and activation of tissue-specific macrophages called microglia (discussed in detail 
below).  Unlike neutrophils which undergo apoptosis, macrophages traffic in and out of the wound 
to remove necrotic and foreign debris [95].  This clean up continues at the current level until the 
blood-brain barrier (BBB) is restored.  In the absence of a foreign body, once the BBB is restored 
the trafficking of monocytes to the wound site is inhibited by down regulation endothelial cell 
selectins [96].   
 Another factor which potentially plays a large role in these initial events is complement 
activation.  Complement activation evolved to removed pathogens and microbes through various 
pathways (classical, lectin, alternative) [97].  Complement activation is important for implanted 
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devices as it has been shown that artificial surfaces activate the complement system in vitro and 
in vivo [98, 99]. 
 Other reactive cell types in neural tissue include tissue-resident macrophages (microglia), 
mast cells, and astrocytes.  Microglia cells are the tissue-resident macrophage of the brain [100].  
They are derived from the yolk sac unlike other circulating monocytes and blood-borne 
macrophages which originate from the bone marrow [101].  In an effort to delineate the role of 
tissue-resident and blood-borne macrophages some approaches use chimera mice, where the 
bone marrow is irradiated and replaced with labeled bone marrow.  These experiments show that 
yolk-sac derived microglia may have a larger role in debris clearance at the acute time points (0-4 
d) as compared to blood-borne macrophages [102].  Conversely, another study with a similar 
mouse model showed that blood-derived macrophages dominate the chronic biotic/abiotic 
interface of an implanted device [103].  However, these approaches do not account for the 
population of bone-marrow derived macrophages that infiltrate and reside in the CNS.  To 
address this, a recent approach used genetic markers to label bone marrow derived cells (via 
HOXB8).  This genetic approach has shown that even in the healthy brain there is a distributed 
population of bone-marrow derived tissue-resident macrophages, which accounts for 
approximately 40% of all brain tissue-resident macrophages [104]. 
 Mast cells, another tissue-resident inflammatory cell type, are most associated with their 
role in anaphylaxis.  They are mostly present in the perivascular space in the brain and in the 
meninges surrounding the brain.  Mast cell activation during neural injury and neuroinflammation 
is hypothesized as a contributing factor to neuronal death following injury, especially due to their 
release of vasoactive mediators and other soluble factors during degranulation [105]. 
 Astrocytes, while most associated with scarring in the injured brain, can also secrete 
proinflammatory cytokines and contribute to neuroinflammation [106].  The inflammatory phase is 
essentially resolved when all damaged/necrotic tissue is removed and the presence of 
proinflammatory macrophages ceases at the site of injury.  Macrophages are not limited to a 
proinflammatory phenotype, their phenotypes exist across a wide spectrum and some contribute 
to the next phase, proliferation [107]. 
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1.4.3  CNS proliferation 
 Proliferation is the next phase of the tissue response in the CNS and is sometimes 
denoted as the repair phase.  The cells most associated with this phase in the CNS are 
astrocytes.  Following injury, astrocytes encircle the injury site which is occupied by neutrophils 
and macrophages.  This astrocyte response is often denoted as astrogliosis, where astrocytes 
develop a hypertrophic cytoskeletal morphology that is believed to develop a barrier around the 
injury site.  At chronic time points this response is denoted as the glial scar.  The degree of 
astrogliosis and glial scarring is related to the initial amount of hemorrhage and tissue damage 
[108].  The glial scar is a particular focus of intervention for SCI patients.  Following injury in the 
spinal cord, the glial scar formation and secretion of inhibitory proteins (e.g., chondroitin sulfate 
proteoglycan or CSPG) prevents axonal regeneration, thus limiting functional recovery [109].  
Similar to neuronal outgrowth inhibition in the spinal cord, cortical neurons cannot transverse the 
glial scar due to these inhibitory molecules.  While this is detrimental for regeneration, strictly 
eliminating astrogliosis is not an option as it has also been shown to be protective.  This 
protective nature was show in a study that looked at the tissue response in the spinal cord when 
reactive astrocytes were selectively deleted in transgenic mice by administration of viral agent 
ganciclovir, which showed that reactive astrocytes are required for wound healing, protected 
neuron, and oligodendrocyte function, and preserved motor function in mild or moderate SCI 
[110]. 
 Unlike other cells involved in CNS injury, differentiated neurons established in the 
cerebral cortex are unable to proliferate and retract their processes or die as a result of the high 
levels of inflammation [76, 111, 112]. 
 
1.4.4  CNS remodeling 
 Remodeling, like neuronal proliferation, is limited in the CNS as compared to peripheral 
tissues.  One reason is the chronic nature of the glial scar, which does not resolve and remains 
above background at chronic time points [76, 77].  When an area of damage is large a CSF filled 
cavity often develops that is encapsulated by hypertrophic astrocytes [113].  The lack of neural 
remodeling and reconstruction is a critical limitation for diseases such as stroke and 
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neurodegenerative diseases, which has prompted interventions that range from growth factor to 
stem cell delivery to promote functional recovery [113, 114].  Additionally, this means that 
iatrogenic injury must be minimized to preserve as much of the natural architecture as possible. 
 
1.4.5  The foreign body response 
 The tissue response detailed above is relevant to a transient injury, however, when a 
device is chronically left indwelling, there is a deviation from this process known as the foreign 
body response (FBR).  The FBR is observed around all chronically implanted biomedical devices, 
materials or research tools including those devices introduced in section 1.2, [44-46, 76, 115].  In 
an effort to understand and improve biocompatibility, FBR to recording MEAs (Fig. 1.2) has been 
an area of considerable focus in recent years.  For this reason, and given the focus of this 
dissertation, the FBR description below focuses on the FBR surrounding intracortical MEAs.  The 
first notable difference in the FBR is that it does not resolve.  A layer of activated, phagocytic 
macrophages is observed adjacent to the interface over the entire indwelling period irrespective 
of the type of device, its material makeup or the species studied.  The response has been called 
frustrated phagocytosis, which eventually leads the fusion of macrophages and the formation of 
multinucleated, foreign body giant cells (FBGC) at the biotic abiotic interface [116-118].  Our lab 
has previously shown that on explanted brain implants these activated proinflammatory 
macrophages release a number of proinflammatory cytokines including monocyte chemotactic 
protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) [76].  A more recent study showed 
the presence of multinucleated FBGCs on the base of a chronically implanted UEA in rat cortex 
[68].  The surface adherent macrophages are believed to be a driving force behind the FBR as 
they secrete a wide array of cytokines, chemokines, and effector molecules which affect tissue 
remodeling and may damage surrounding neural tissue [111, 118-122]. 
 Immediately beyond the macrophage layer is a layer of hypertrophic astrocytes.  Similar 
to the glial scar that forms following injury, the astroglial scar associated with device interfaces 
does not resolve and is known to secrete proinflammatory cytokines [106, 123].  Associated with 
this persistent inflammation is a leaky blood-brain barrier (BBB) as identified by plasma proteins 
that are present in the brain parenchyma throughout the indwelling period [124, 125].  This sets 
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up a recurring loop as plasma proteins can induce inflammation in the brain and inflammation, in 
turn, causes BBB leakage due to monocyte recruitment [126, 127]. 
 Neurons are highly susceptible to mechanical damage as well as changes (ionic, 
osmotic, metabolic, effector molecules, etc.) in the complex extracellular milieu [128-131].  Most 
researchers have reported a loss of neuronal cell bodies and their processes adjacent to the 
electrode-tissue interface [76, 132].  Furthermore, altered excitability in the tissue surrounding the 
device may also influence recording MEA functionality [76, 133].  This is particularly problematic 
for the advancement of neural recording devices, as single unit AP measurements require a 
distance of less than 140 μm between the electrode and adjacent neuronal cell bodies [134, 135].  
Following these observations, a leading theory to improve the long term efficacy of recording 
devices is to decrease the FBR [68, 132, 136, 137]. 
 The brain’s FBR is the most common focus for improving the chronic single unit recording 
of cortically implanted MEAs.  However, most of the devices detailed in section 1.2 require 
supporting components that exist outside of the cranial vault which require anchorage to the skull 
and must transverse several layers of noncortical tissue.   
 One example of noncortical tissue that significantly influences the functional longevity of 
recording MEAs is the meningeal layers.  The meninges include the dura, arachnoid, and pia 
maters.  Although these layers exist inside of the cranial vault and support neural function, they 
are mostly composed of fibroblasts and fibrous collagen, unlike the brain [138].  As noted in 
section 1.3, a failure mechanism of cortically-implanted UEAs is fibrous encapsulation by 
meningeal layers, which are originally removed above the implantation site and grow back.  This 
thick fibroblast driven encapsulation can cause the MEA to be completely isolated from all neural 
tissue [49, 63, 139, 140].  Lastly, an issue which is seldom discussed as a biological problem in 
literature is the failure and dislodgment of headstage components [49, 58].  Headstage 
dislodgement is often categorized as a mechanical failure, even though the etiology is partially 
biological due to animal grooming but can also occur due to osteolysis surrounding bone screws 
which results in bone screw loosening.  Additionally, the influence of these components on the 
underlying neural tissue was previously unknown, but is addressed in section 1.9 and Chapter 3. 
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1.5  Previous Efforts to Minimize the FBR to CNS Implants 
 
 Improved biocompatibility is the ultimate goal of studies that seek to minimize the FBR.  
Towards this end, a number of studies have focused on systemic pharmaceutical intervention, 
local drug elution, modification to the device geometry, and surface coatings.  The majority of the 
techniques are directed towards recording MEAs to establish the contemporary work for the 
model system used in this dissertation. 
 
1.5.1  Systemic pharmaceutical administration 
 Systemic pharmaceutical interventions have focused on the inflammatory response to 
cortical implants [141, 142].  One investigation analyzed the influence of systemic anti-
inflammatory treatment on MEA recording function by orally administering minocycline, a 
tetracycline antibiotic.  The rationale for using minocycline, a tetracycline antibiotic, is its 
neuroprotective effects when administered following CNS injury or for neurodegenerative 
diseases.  While the exact mechanism of this neuroprotection is unknown, it has been postulated 
that the root cause is inhibition of microglia activation and excitotoxicity [143].  Their results 
showed that the minocycline treated group had a higher signal-to-noise ratio, more functional 
recording channels, and a lower area of astrocyte (GFAP) immunolabeling [144].  Drawbacks of 
this approach were the limited time points and that minocycline is not a viable chronic solution 
due to side effects.  Regardless, the experiment indicates a relationship between the FBR, 
specifically astrogliosis, and functional performance. 
 
1.5.2  Local drug and small molecule elution 
 Local drug elution is another technique which builds off of the concept of influencing the 
FBR through anti-inflammatory agents or growth factors but avoids the systemic complications.  A 
number of studies have investigated elution of dexamethasone (DEX) as a means to decrease 
the FBR [145, 146].  The rationale for using dexamethasone, an anti-inflammatory glucocorticoid 
hormone, is based on studies using systemic injections which decreased astrogliosis around CNS 
implants [141].  The mechanism of action for this decrease in astrogliosis is attributed to 
dexamethasone’s immunosuppressant/anti-inflammatory properties.  However, systemic 
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administration has a number of dangerous side effects, thus prompting its incorporation into a 
coating for elution [147].  A study from the Bellamkonda lab showed that MEAs with DEX eluting 
coatings significantly decreases astrogliosis (GFAP) at both 1 and 4 weeks.  However, while 
inflammation was significantly decreased at 1 week, the benefit was lost at 4 weeks [148].  
Another study on DEX elution focused on electrical impedance and showed that impedance did 
not increase within the first 2 weeks surrounding DEX eluting coating, as compared to uncoated 
controls which approximately tripled [149].  Other small molecules eluted from the interface 
include alpha-melanocyte stimulating hormone (α-MSH) and Interleukin-1 receptor antagonist (IL-
1ra) that both act as anti-inflammatory agents, and nerve growth factor (NGF) that would 
supposedly influence neurite growth and neuronal survival [150-152].  One problem with the drug 
elution approach is the finite supply and lifespan of the eluted drug.  A different proposed method 
to circumvent this and provide unlimited local drug elution is the integration of drug infusion 
cannula into 2D planar MEA [153].  For injuries to the spinal cord a great deal of work has 
focused on altering the glial scar to be permissive for neuronal regeneration.  These techniques 
include injectable hydrogels which target either the degradation or alteration of CSPG sulfation or 
cellular grafts which promote axonal growth via neurotrophic factors [154-157].  Additionally, the 
implantation of scaffolds to instruct neuronal pathfinding via growth factors or genetic 
manipulation has been investigated [158, 159]. 
 
1.5.3  Device geometry and constitutive modification 
 Device geometry and constitutive property modification includes alterations of shank size, 
spacing, inclusion of barbs to maintain position and organization (i.e., braided microwires), and 
device stiffness [34, 160-162].  There are two primary rationales for modifying the architecture 
and constitutive properties of MEAs.  The first rationale is based on surface-adherent 
macrophages, which secrete factors that shape the FBR, being influenced by device geometry 
and permeability that facilitate clearance of proinflammatory cytokines [76, 136, 163].  The 
second rationale is based on notion that mechanical mismatch between the stiff device and soft 
neural tissue continuously damages tissue at the biotic-abiotic interface due to micromotion [164, 
165].  The influence of surface area was investigated by creating a lattice designed electrode with 
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openings along the shank [163].  The important feature of this lattice design was that it maintains 
the same penetrating profile as a solid MEA, which resulted in an equivalent iatrogenic injury.  
The FBR around the lattice MEA was significantly less, with macrophage activation (CD68) and 
BBB leakiness (IgG) being significantly less than solid controls and neuronal density (NeuN) 
being significantly higher than solid controls.  A proposed source of this improvement was the 
decreased amount of surface adherent macrophages (due to less surface area) and an increase 
in the clearance of proinflammatory factors secreted by the surface adherent macrophages.  
Interestingly, the level of astrogliosis was not influenced at chronic time points.  Along with other 
studies which look at the time course of astrogliosis, this indicates that the acute factors are 
influential in the chronic astrogliosis [73]. 
 A concept related to surface area and increased cytokine clearance is that of interfacial 
permeability [136].  To test this, a 400 μm thick hydrogel (alginate) coating was applied to a MEA 
and compared to uncoated controls.  Results showed that even though this coating had a larger 
surface area than an uncoated control, the level of macrophage activation (CD68), astrogliosis 
(GFAP), and BBB leakiness (IgG) was significantly less and neuronal density (NeuN) was 
significantly higher than solid controls.  Another aspect of the hydrogel coating to consider is its 
pliable nature.  Low modulus MEAs are proposed by several groups as means to limit the 
mechanical mismatch between the stiff device and compliant brain tissue [164-166].  However, 
dissecting the relationship between permeability and mechanical mismatch has been challenging 
due to the innate permeability of compliant materials.  Recent and future material science 
developments in nanoporous materials (i.e., silicon and gold) should allow for a better 
understanding of the relationship between permeability, surface area, and device modulus [167, 
168]. 
 
1.5.4  Synthetic polymer and protein coatings 
 Lastly, device surface coatings composed of either synthetic polymer or proteins have 
been investigated for their influence on the FBR [169-171].  The approach of many of these 
coatings is unclear as they list vague mechanisms of action or rationales which are not 
biologically-centric.  One study on synthetic insulator, Parylene-C, does list a rationale of reducing 
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microglia cell attachment [73, 121].  In this study on the electrode insulator Parylene-C, which 
facilitates significantly less cell attachment than bare glass in vitro, there was no influence on the 
FBR.  This contributes to the view that an inert coating does not alter the FBR.  Alternatively, a 
number of groups have investigated bioactive single protein coatings which were not designed for 
elution, but are tethered to the interface.  These include neural adhesion molecule L1 and 
CDPGYIGSR peptide (facilitate cell adhesion and neurite extension), gelatin (acts a degradable 
support), and IL-1ra (binds inflammatory molecules) [172-176].  In one study laminin-1 
(polyanion) was coated onto the surface of a MEA via a layer-by-layer (LbL) deposition with 
polyethyleneimine (PEI, polycation) with the general rationale of promoting tissue integration 
[177].  Compared to uncoated controls, the LbL laminin-1/PEI coating significantly increased 
macrophage activation (CD68) at 24 h, no difference at 1 week, and a significantly decreased 
macrophage activation at 4 weeks.  Astrogliosis (GFAP) surrounding this coating was no different 
than controls at 24 hr and 1 week, however, it was significantly decreased at the 4-week time 
point.  There was no observed difference in the neuronal density. 
 These strategies have had mixed results in regards to their influence on the FBR.  The 
vast majority have focused on the inflammatory and proliferative process, with a few focusing on 
neurotropism and cell adhesion.  The similar nature of the above quantification approaches most 
likely originates from the referencing of the qualitative Szarowski 2003 and quantitative Biran 
2005 publications [76, 178].  For these previous studies, the typical indwelling endpoints range 
from 1 week to 16 weeks, and cohort sizes range from 4-9 animals.  While inflammation was a 
common target for strategies discuss in this section, none of these approaches specifically 
addressed the first instigator of inflammation, the initial hemorrhage. 
 
1.6  Hemorrhage and Hemostasis in the CNS: 
 
Background for Hemostatic ECM Coatings 
 
 Cerebrovascular damage occurs during the insertion of any device into the brain.  The 
resulting hemorrhage is evident following the acute insertion of a MEA into human cortical tissue, 
as shown in Fig. 1.3.  Hemostatic mechanisms stabilize the hemorrhage and limit neuronal cell 
death [82].  During hemostasis, platelets play many critical roles following their adhesion, 
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activation, and aggregation.  Platelets form the primary hemostatic plug and undergo 
degranulation; releasing factors which directly accelerate the coagulation cascade [179].  The 
initial adhesion and subsequent activation of platelets is induced by specific binding motifs 
located on extracellular matrix (ECM) proteins, which compose the vascular basement 
membrane.  Of these proteins, collagen and laminin are known to initiate adhesion and activation 
through the platelet glycoprotein VI receptor pathway [180, 181].  Collagen, the most abundant 
protein in the ECM, specifically induces platelet activation through the recognition of Gly-Pro-Hyp 
peptide sequence [182].  Laminin, via integrin α6β1, supports extensive platelet spreading and 
specifically stimulates the formation of filopodia and lamellipodia [183].  Other ECM proteins 
known to aid in platelet adhesion are fibronectin and vitronectin [184].   
 In the clinical setting, collagen powders and sponges have served as the gold standard 
for managing bleeding.  In vitro studies using clinically-available topical hemostatic agents 
indicate that noncrosslinked collagen is the most effective mechanical inducer (no thrombin) of 
hemostasis when compared to gelatin and cellulose [185].  To leverage these hemostatic 
abilities, investigational endovascular coils have been coated with ECM proteins to promote 
coagulation of blood inside of an aneurysm [27].  Cumulatively, these studies indicate that 
mimicking the heterogeneous protein composition and available binding motifs of the vascular 
basement membrane would be an effective strategy for accelerating hemostasis. 
 
1.7  The Role of ECM in Immunomodulation and CNS Wound Healing: 
 
Background for Immunomodulatory ECM Coatings 
 
 Acellular tissue engineering scaffolds composed of ECM proteins have demonstrated an 
ability to direct the tissue response towards a proregenerative phenotype.  This, in part, is  
attributed to the immunomodulatory abilities of ECM.  Brown et al. showed that implanted 
biologically-derived meshes induce a higher ratio of alternatively activated, proregenerative 
macrophages to classically activated, proinflammatory macrophages.  The initial ratio of 
proregenerative to proinflammatory macrophages was correlated to differences in chronic tissue 
remodeling [186].  Furthermore, acellular ECM constructs are able to induce a higher ratio of 
proregenerative macrophages in comparison to cellular constructs; even autologous cellular 
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constructs resulted in a dominant proinflammatory macrophage response [187].  When ECM was 
used as a coating for subdermal implants, the degree of fibrosis was significantly decreased 180 
days post implantation [188]. 
 Modulating macrophage phenotype and their secreted factors may be especially 
beneficial in the CNS since proinflammatory macrophages are neurotoxic and proregenerative 
macrophages promote axonal regeneration and dendritic pruning [189-191].  Injection of a 
hydrogel ECM in the CNS following traumatic brain injury was able to attenuate local damage 
[192].  Additionally, studies have shown that nonsoluble factors, such as ECM proteins, secreted 
from cells alter the morphology and inflammatory processes of CNS tissue-resident macrophages 
[193-196].  Taken together, these studies indicate that ECM may improve the tissue remodeling 
following CNS injury through immunomodulation. 
 
1.8  Fixation and Neuroinflammation of Chronic CNS Devices: 
 
Background for Headstage FBR Analysis 
 
 As mentioned in section 1.4.5, devices implanted in the CNS require anchorage to other 
tissues in order to perform their intended function.  This is especially true for in vivo animal 
studies due to animal interactions or specific grooming behaviors, which might loosen or remove 
the device.  For the most part, all investigational devices in section 1.2 are fixed to the skull with 
similar techniques (Fig. 1.4). 
 
1.8.1  Fixation techniques for chronic CNS devices 
 These techniques include anchorage to screws attached to the skull, and encapsulation 
of the screws and transcutaneous connector in a cement or adhesive to form a headstage [58, 
70, 197, 198].  One reason for this similarity in device anchorage is, especially in recording 
devices, the comparable size and design of the electrical connectors.  The standard nature of the 
connectors is an important aspect as it allows a group to easily connect several different types of 
recording devices to the same testing or recording apparatus [70].  The size of the animal dictates 
the number of implants and the corresponding size of the headstage [198].  For example, the size 
of the nonhuman primate (NHP) brain and skull enables the use of larger MEAs as well as a 
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larger pedestal and  screws for anchorage [49].  The NHP skull is also significantly thicker, which 
allows for better thread engagement between the screw and bone.  Conversely, in rodents, 
headstage fabrication is limited to the use of screws and adhesive encapsulation to anchor the 
MEA to the skull [60, 68, 197, 199-202].  Similar screw and adhesive encapsulation techniques 
are used experimentally for deep brain stimulators, hydrocephalic shunts, optogenetic fiber optic 
probes, microdialysis probes, push-pull cannulas, tubing for drug infusion, and cranial windows 
used in advanced microscopy studies [119, 139, 203-206].  The skulls of rodents are much 
thinner and vary with age, which limits the strength of screw fixation in comparison to NHPs.  
Furthermore, the primary device component (recording or stimulating MEA, optogenetic probe, 
microdialysis cannula, etc.) makes up a small percentage of the entire implanted surface area. 
 While significant attention has been directed to studying the FBR to MEAs implanted in 
cortex, little attention has been directed to studying the FBR associated with the other headstage 
components that are used to secure MEAs to the skull during chronic use.  Fixation screws (Fig. 
1.5) are of special interest as they generally penetrate the skull to make contact the meninges 
and the underlying brain tissue. 
 
1.8.2  Neuroinflammation and neural function 
 Emerging evidence on neuroinflammation and its impact on opening the BBB, decline in 
neurogenesis, and reductions in cognitive function suggest that the scientific community should 
consider the headstage and its associated components an integral part of the MEA [203, 207, 
208].  One group employed a cortically-implanted electrode and cannula to directly stimulate 
neuroinflammation via lipopolysaccharide (LPS) infusion, and showed that the treatment 
decreased hippocampal neurogenesis [208].  Moreover, other groups have shown that chronic 
inflammation outside the CNS has detrimental effects on neurogenesis [207, 209, 210] as well as 
on neural connectivity [211].  One study mapped the widespread macrophage and glial activation 
using autoradiography of [3H]PK11195 in the rat brain accompanying the use of a deep brain 
stimulator (DBS).  The DBS was fixed to the skull with multiple screws and acrylic dental cement.  
The results showed widespread and persistent neuroinflammation over an 8-week indwelling 
period that was accompanied by cognitive deficits, as determined by an object recognition test 
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[203].  Studies which have looked at the impact of a craniotomy alone showed neuroinflammation 
notion that inflammation resulting from an indwelling device or surgical procedure, either located 
and functional deficits 2 weeks following surgery [212, 213].  Together, such studies support the 
notion that inflammation, within the brain or systemically, can impact global brain function and not 
just at the environment surrounding the implanted MEA.  In an effort to improve the 
biocompatibility of the device as a whole, an understanding of FBR to all of the components of the 
device may be required to maximize biocompatibility. 
 
1.9  Introduction to This Dissertation 
 
 CNS implanted devices are an important therapeutic option for CNS diseases and a vital 
investigative tool used in basic neuroscience research.  However, poor functional longevity has 
limited its impact in research and in clinical medicine.  It is currently held within the scientific 
community that the decreases in single unit recording function is associated, in part, with the 
foreign body response (FBR) that surrounds implanted devices; which includes persistent 
inflammation, astrogliosis, BBB leakiness, demyelination, and neuronal cell death.  Two potential 
areas for intervention are in limiting the initial hemorrhage that results from device insertion and 
the subsequent neuroinflammatory sequela.  As already discussed, cellular interactions with 
extracellular matrix (ECM) have been shown to promote hemostasis and possess 
immunomodulatory properties.  The central hypothesis driving this work was that ECM coatings 
which target initial hemorrhage and aspects of neuroinflammation will decrease the FBR at 
chronic time points.  This was investigated by coating silicon MEAs with ECM proteins and 
implanting them into the cortex of Sprague-Dawley rats.  The approach was identical to that used 
in previous studies from our lab that investigated device geometry modifications and hydrogel 
coatings [136, 163], and was similar to other studies who have investigated the foreign body 
response (FBR) to MEAs implanted in the rat CNS [73, 136, 145, 148, 150-152, 169-173, 175-
177, 214-222]. 
 First, based on the rationale of promoting hemostasis (section 1.6), it was hypothesized 
that a coating developed from a FDA-approved neurosurgical hemostatic agent, Avitene™ 
Microfibrillar Collagen Hemostat (MCH), would decrease aspects of the FBR including 
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inflammation, astrogliosis, BBB leakiness, and neuronal death over the chronic time point.  In 
vitro assays on Avitene coatings confirmed its hemostatic properties, but showed no 
immunomodulatory potential using a microglial activation assay in vitro.  Quantitative 
immunohistochemistry of the FBR to chronic implanted Avitene coated MEAs showed that there 
was a significant increase in IgG within the recording zone.  Additionally, there was no significant 
influence on CD68, GFAP, or NeuN density compared to uncoated controls.  To the best of my 
knowledge the Avitene coating is the first protein coating applied to a recording MEA that did not 
result in a significant decrease in any of the classic FBR hallmarks.  Interestingly, the increase in 
IgG may indicate an enhancement of late phase neuroinflammation or possibly an unresolved 
provisional matrix. 
 Second, based on the rationale of using a hemostatic agent that also possesses 
immunomodulatory properties (section 1.7), it was hypothesized that a coating developed from an 
allogeneic tissue-specific ECM would decrease the FBR including inflammation, astrogliosis, BBB 
leakiness, and neuronal death over the chronic time point.  The ECM for this coating was derived 
from allogenic astrocytes harvested from the cortex of postnatal Sprague-Dawley rats.  In vitro 
assays showed that astrocyte-derived ECM possessed hemostatic properties similar to Avitene, 
and, unlike the Avitene coating, showed an ability to reduce the activation of microglial in an in 
vitro assay.  It was found that the astrocyte-derived ECM coating, decreased the amount of GFAP 
within the recording zone compared to uncoated controls but found no additional benefits of its 
use on reducing other aspects of the FBR.  This decrease in astrogliosis may improve device 
functionality, as previous studies have shown that elevated astrogliosis is associated with poor 
single unit recording performance [45, 55, 60, 68, 124]. 
 Collectively, the results of these studies show that ECM coatings with different genetic 
background and compositions are able to differentially affect specific aspects of the FBR 
surrounding single-shank, silicon MEAs.  Given the relationship between the Avitene MCH and 
the astrocyte ECM coatings, their methods and results have been combined to present one body 
of work in Chapter 2. 
 The third study presented in this dissertation focuses on the FBR to CNS devices as a 
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whole.  While the electrode-tissue interface has been studied extensively, the FBR to other 
essential headstage components was unknown.  In this study the central hypothesis was that 
headstage components used to anchor microelectrode arrays to the rodent skull contribute to the 
neuroinflammatory burden.  To address this, a retrospective analysis that included 38 rats 
implanted with neural recording devices correlated screw locations with FBR in underlying cortical 
tissue.  Results showed that, macroscopic damage associated with the headstage components 
occurs beneath 86% of bone fixation screws and characterized the associated FBR on the 
cellular and molecular levels.  The impact of understanding how fixation techniques, common for 
a wide variety of neurological studies, influence the cerebral cortex and provide a reference for 
future biologically-informed device design.  The results shown in Chapter 3 are compounded by 
emerging data on device-related neuroinflammation and the subsequent decline in neurogenesis 
and cognitive function [203, 207, 208]. 
 In summary, the dissertation as a whole endeavors to first, decrease the known 
detrimental aspects of implanted CNS devices through biologically-inspired coatings, and second, 






Fig. 1.1.  Vasculature of the rodent brain.  (A) SEM image of vascular corrosion cast of 
whole mouse brain with the olfactory bulb on the right side.  Visible are the ascending 
middle cerebral artery of the right cortex (black arrow) and the venous drainage at the 
surface [223].  (B-D) Histological reconstruction and vectorization of neurovasculature 
networks in mouse brain.  (B) Top view of reconstructed pial arteriolar and venular 
networks that feed and drain the (C) penetrating arteriole and venules, respectively.  These 
penetrating vessels supply and drain the dense subsurface microvasculature which is (D) 
organized into different communities throughout the depth and breadth of the cortex. 
(A) Reprinted by permission from John Wiley and Sons: Microscopy Research and 
Technique, T. Krucker, A. Lang, E. P. Meyer, New polyurethane-based material for vascular 
corrosion casting with improved physical and imaging characteristics, Microsc. Res. Tech. 
69 (2006) 138-147. http://dx.doi.org/10.1002/jemt.20263. [223], Copyright 2006.  (B-D) 
Reprinted by permission from Macmillan Publishers Ltd (Nature Publishing Group): Nature 
Neuroscience, P. Blinder, P. S. Tsai, J. P. Kaufhold, P. M. Knutsen, H. Suhl, D. Kleinfeld, 
The cortical angiome: an interconnected vascular network with noncolumnar patterns of 
blood flow, Nat. Neurosci. 16 (2013) 889-897. http://dx.doi.org/10.1038/nn.3426. [224], 





Fig. 1.2.  Stereotypical FBR in the rodent brain.  Biomarker immunoreactivity and 
quantification using cell-type-specific markers at the microelectrode–brain tissue 
interface.  (A) Representative images collected from two adjacent sections of an animal 
with a 4-week microelectrode implant illustrate the general appearance of the foreign body 
response characterized by inflammatory (ED1) and astrocytic (GFAP) cell phenotypes 
adjacent to the implant interface.  The area of inflammation and intense astrocyte 
reactivity contains a reduced number of NeuN+ neuronal bodies and a loss of 
neurofilament (NF) density.  The position of the microelectrode is illustrated by the orange 
oval (drawn to scale) at the left of each image.  (B) Quantitative line profile intensity 
analysis of ED1 (blue line), GFAP (black line), and neurofilament (red line).  Mean pixel 
intensity per distance point for 2-week (top row) and 4-week (bottom row) time points for 
stab wounds (left column) and chronic microelectrodes (right column).  The average 
standard error of the mean around each data point ranged from 4% to 14% of the mean 
value.  Note that the GFAP response does not return to background levels at 4 weeks 
following a transient stab wound injury. 
Reprinted by permission from Elsevier: Biomaterials, R. Biran, D. C. Martin, P. A. Tresco, 
Neuronal cell loss accompanies the brain tissue response to chronically implanted silicon 
microelectrode arrays, Exp. Neurol. 195 (2005) 115-126. 





Fig. 1.3.  Acute hemorrhagic response to cortically implanted MEAs.  Gross specimens of 
human temporal lobe implantations and scanning micrographs of the surface of the UEA 
after acute implantation in human brain.  (A) Placement of an electrode array in temporal 
cortex.  (B) Hemorrhages in electrode tracks following array removal.  (C-D) Horizontal 
section showing blood in the electrode tracks and petechial hemorrhages (white arrows 
and box) located below the tip of the electrodes.  (E-F) Scanning electron micrograph of a 
MEA tip shows red blood cells adherent to the surface.  Scale bars A, B, C and D = 2 mm. 
Reprinted by permission from Frontiers: Frontiers in Neuroengineering in accordance with 
open-access article terms, E. Fernandez, B. Greger, P. A. House, I. Aranda, C. Botella, J. 
Albisua, et al., Acute human brain responses to intracortical microelectrode arrays: 
challenges and future prospects, Front. Neuroeng. 7 (2014) 24. 





Fig. 1.4.  Representative headstages for various CNS experiments in rodents including (A) 
cannulation and fiberoptic light delivery for optogenetics, (B) cranial windows for in vivo 
cellular and molecular imaging, and (C-D) MEAs for recording and stimulation of single 
neurons or neuronal clusters.  While the implanted devices have dramatically different 
investigational uses, the techniques to secure them are essentially the same. 
(A) Adapted by permission from Macmillan Publishers Ltd (Nature Publishing Group): 
Nature Protocols, J. G. McCall, T. I. Kim, G. Shin, X. Huang, Y. H. Jung, R. Al-Hasani, et al., 
Fabrication and application of flexible, multimodal light-emitting devices for wireless 
optogenetics, Nat. Protoc. 8 (2013) 2413-2428. http://dx.doi.org/10.1038/nprot.2013.158. 
[204], Copyright 2013.  (B) Adapted by permission from Macmillan Publishers Ltd (Nature 
Publishing Group): Journal of Cerebral Blood Flow & Metabolism, A. Y. Shih, J. D. Driscoll, 
P. J. Drew, N. Nishimura, C. B. Schaffer, D. Kleinfeld, Two-photon microscopy as a tool to 
study blood flow and neurovascular coupling in the rodent brain, J. Cereb. Blood Flow 





Fig. 1.5.  Representative stainless steel anchorage screws used for headstage fabrication 
in rodents include a (A) self-tapping bone screw (#19010-00, 1.17 mm diameter, 18/8 grade 
SS, Fine Science Tools (FST), Foster City, CA) and (B) blunt machine screw (#B-MX-172-3, 
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2.1  Introduction 
 
 The foreign body response (FBR) negatively impacts the biocompatibility of various 
devices chronically implanted in the brain, including hydrocephalic shunts, deep brain stimulation 
electrodes, and intracortical recording microelectrode arrays (MEAs) [44, 45, 49].  Several efforts 
have targeted the inflammatory sequela of the FBR with bioactive agents, either delivered locally 
or systemically [141, 144, 148, 215].  This inflammatory sequela is initiated by bleeding that 
occurs following device insertion [225].  In particular, plasma proteins including complement and 
immunoglobulins activate macrophages and initiate the downstream events involved in wound 
healing and the FBR [226, 227].  For over a century, it has been known that products of 
hemorrhage elicit a phagocytic response [228].  In particular, plasma proteins including 
complement and coagulation components activate macrophages and initiate the downstream 
events involved in wound healing and the FBR [226, 227].  A recent report using two-photon in 
vivo imaging in neural tissue showed that serum protein leakage through the blood-brain barrier 
(BBB) induced a rapid inflammatory reaction which was correlated with areas of axonal damage 
and reactive oxygen species release [129].  Furthermore, the plasma protein fibrinogen has been 
shown to specifically activate astrocytes and drive the glial scar through modulation of TGF-β 
availability [229].  Several studies have shown that both the size and type of damaged 
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vasculature has a significant influence on the degree of damaged neural tissue [230].  These 
effects of hemorrhage on the health of surrounding brain tissue is a major concern [82], which 
applies to all implanted devices irrespective of the type of implant, species studied, or 
implantation method [88, 178] 
 To the best of my knowledge, no one has investigated the use of extracellular matrix 
(ECM), which naturally regulates hemorrhage, as a coating to see if promoting hemostasis can 
modulate the FBR to devices implanted in the CNS.  Additionally, emerging evidence indicates 
that ECM from a number of sources is able to modulate macrophage activity towards a 
proregenerative phenotype [231, 232].  Therefore, an ECM surface coating that promotes 
hemostasis and modulates macrophage activity may lower the FBR, and by definition improve 
device biocompatibility.  To address this hypothesis, we chose to study the effect of a coating 
developed from Avitene™, a FDA-approved absorbable microfibrillar collagen hemostat (MCH) 
derived from bovine dermis [185, 233].  Additionally, we choose to investigate an ECM derived in 
vitro from rat cortical astrocytes.  The influence of these two ECM coatings on the FBR hallmarks 
was immunohistochemically quantified surrounding a single-shank silicon MEA implanted in 
Sprague-Dawley rat motor cortex, which has been used as a model system for such studies [73, 
76, 103, 125, 132, 136].  Moreover, the presented work seeks to address the FBR, which has 
been identified as an obstacle to the widespread clinical use of intracortical recording MEAs [49, 
68, 74, 124]. 
 
2.2  Methods 
 
2.2.1  Allogeneic astrocyte ECM derivation 
 Cell-specific ECM was derived from primary rat astrocytes as previously described [234].  
First, open-celled polymeric foams were fabricated by dissolving pellets of medical grade 
polyurethane (PU) elastomer (Tecoflex SG-80, Thermedics, Woburn, MA) in dimethylacetamide 
(DMAC) (1:10 w/v) overnight at 60°C [234-236].  A poloxamer solution (Pluronic 10R5, BASF, 
Germany) is then added to the dissolved PU (1:2 v/v) and thoroughly mixed.  The solution is then 
cooled to its cloud point at 46°C, and pipetted it into polyoxymethylene (Delrin) molds.  The 
solution and molds are then rapidly cooled through surface contact in a dry-ice/ethanol bath to 
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induce a phase inversion.  The molded, phase-inverted solution is then precipitated in DI H2O 
overnight.  Following precipitation, the resulting foams are removed from the molds, rinsed with 
multiple washes of DI H2O, frozen to -80°C, and lyophilized.  Lyophilized foams are sectioned into 
strips (30 mm x 10 mm x 2 mm) and attached to biaxially-oriented polyethylene terephthalate 
(Mylar) mounts using a medical grade, UV curable adhesive (MD 1180-M, Dymax, Torrington, 
CT).  Mounted foams were sterilized using ethylene oxide (EtO).  Following EtO sterilization 
foams are soaked in 70% ethanol for 20 min to promote wetting followed by rinsing in sterile DI 
H2O.  To promote cellular attachment, foams are incubated in a fibronectin (FN) solution (20 
μg/mL in PBS) overnight. 
 Following FN incubation, PU substrates were seeded with primary astrocytes, harvested 
from Sprague-Dawley rat pups as previously described, at two million cells/cm3 [237].  Astrocyte 
seeded substrates were cultured for 3 weeks in DMEM F12 supplemented with 10% fetal bovine 
serum (FBS), with media exchanged every 2 to 3 days. 
 Following culture, samples were rinsed in DI H2O and frozen to -80°C.  PU removal was 
performed as described previously with samples being soaked in the solvent DMAC for 72 h.  The 
solvent was exchanged 7 times during the 72-hr period, 3 times on the first day and then twice 
daily thereafter. 
 The extracted material (Fig. 2.1) was then processed with decellularization techniques as 
previously described [234, 238].  First, samples were immersed in hypotonic Tris-Hcl buffer (10 
mM, pH 8.0) with 0.1% EDTA and 10 KIU/mL aprotinin (Sigma) for 1-2 hr at room temperature 
(RT) to disrupt integrin-ECM interactions and deactivate proteases that were released due to cell 
lysis.  Second, samples were immersed in Tris-Hcl buffer containing 0.1% SDS (10 mM, pH 8.0) 
on a rocker at 100 rpm at RT overnight to remove lipids.  Third, samples were rinsed in PBS (3 
times, 30 min each), then immersed in Tri-Hcl buffer (50 mM, pH 7.5) containing ribonuclease (1 
U/mL, Sigma) and deoxyribonuclease (50 U/mL, Sigma) on a rocker at 37°C for 3 hr to remove 
nuclear material.  Samples are then rinsed again in PBS on a rocker (3 times, 30 min each).  To 
assess the effectiveness of the decellularization process, samples were stained with DAPI (4',6-
Diamidino-2-Phenylindole, Dihydrochloride, Life Technologies, Carlsbad, CA, 10 μM) and 
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immunolabeled for the astrocyte cytoskeletal component GFAP (DAKO, Carpinteria, CA, 2.9 
μg/mL).  Following PU removal and decellularization steps, the remaining material was rinsed  
7 times in DI H2O, frozen, and lyophilized. 
 
2.2.2  Proteomic characterization of astrocyte-derived extracellular matrix 
 The ECM of the FDA-approved Avitene MCH has been extensively characterized and is 
composed primarily of type-1 collagen, which is essential for blood clotting [185, 233].  To identify 
extracellular matrix components in the astrocyte-derived ECM with similar properties, samples 
were analyzed with tandem mass spectroscopy (MS/MS) using similar methods as described 
previously [234].  In brief, the cell derived material sample was washed with 50 mM ammonium 
bicarbonate, denatured (Protease Max, Promega, Madison, WI) for 30 min at room temperature, 
trypsin (20 ng/µl) digested overnight at 37°C, and purified (Ziptip, Milipore, Billerica, MA).  The 
MS/MS analysis was performed by the University of Utah Mass Spectroscopy & Proteomic Core 
Facility using a hybrid mass spectrometer (LTQ-FT, Thermo Scientific, Waltham, MA).  Primary 
peptide molecular mass spectra were acquired by Fourier transform ion cyclotron resonance.  
The sequencing of individual peptide spectra was performed by collision-induced dissociation in 
the linear ion trap.  Sample proteins were identified by comparison of MS/MS measured peptide 
sequences to a trypsin-cut specific protein database (Mascot version 2.2.1, Matrix Science Inc., 
Boston, MA). 
 In addition, samples of the ECMs, Avitene and astrocyte-derived, were analyzed using 
indirect immunohistochemistry for fibronectin (CFN; Sigma, St. Louis, MO, 14 μg/mL), laminin 
(LN; Sigma, St. Louis, MO, 1.38 μg/mL) and chondroitin sulfate (CS-56; Sigma, St. Louis, MO, 
3.2 μg/mL).  In brief, antibodies were diluted in a detergent-free blocking solution consisting of 4% 
(v/v) goat serum (Invitrogen, Carlsbad, CA) and 0.1% (w/v) sodium azide in PBS.  Free-floating 
material samples were batch treated for 1 hr in a detergent-free blocking solution at room 
temperature, followed by incubation with primary antibodies overnight at 4°C.  After 3 washes in 
PBS to remove excess antibody (1 h/rinse), appropriate fluorescently labeled secondary 
antibodies (Molecular Probes, Eugene, OR) were applied in block for 1 hr at room temperature, 
followed by three washes in PBS (1 h/rinse).  Fluorescent images were captured with a Coolsnap 
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digital camera on a Nikon Eclipse E600 microscope.  Immunoreactivity was compared to no 
primary controls to confirm specificity. 
 
2.2.3  Nanoscale morphological assessment of adsorbed Avitene MCH 
 Transmission electron microscopy (TEM) images were obtained using a FEI Tecnai T12 
microscope (FEI, Hillsboro, OR) operating at 120 kV.  To prepare TEM samples, 10 μL of Avitene 
in DI H2O was adsorbed onto the surface for 1 min, excess fluid was removed with blotting paper.  
Next, 10 μL of 2% uranyl acetate solution was applied to the adsorbed Avitene to stain the 
sample on a copper grid covered with a thin carbon film.  The sample was then dehydrated 
overnight at room temperature (RT). 
 
2.2.4  Extracellular matrix coating solution  
 Both Avitene, microfibrillar collagen purified from bovine corium (dermis) and sterile 
processed [239], and astrocyte-derived ECM were suspended in 0.25 M acetic acid solution 
(sequencing-grade aldehyde-free BP1185, Fisher Scientific Company, Ottawa, Ontario) at a 
concentration of 1 mg/mL in a 50 mL conical tube and stirred at room temperature for 24 h.  A 
nylon 70 μm cell strainer was used to remove large aggregates of material.  All processing steps 
utilized sterile reagents and were performed in a sterile environment. 
 
2.2.5  Lee-White clotting time assessment 
 Human blood drawn into 105 mM sodium citrate solution (1 mL citrate / 9 mL blood) was 
transferred to a 37°C water bath until testing.  100 μL of the suspended Avitene or astrocyte-
derived ECM was pipetted against the inner wall of a 1.5 mL conical centrifuge tube and dried 
under sterile nitrogen flow.  Citrated blood was added (450 μL) to coated and uncoated control 
tubes.  Then 50 μL of 100 mM CaCl2 was added to the tube, which signified the start of the 
clotting time measurement.  Vials were incubated in water bath and tilted every 30 seconds until 
the blood formed a solid clot that remained adhered to inverted tube.  The time until this clot 
formation was recorded for all groups and repeated for accuracy.  Data sets were normalized to 




2.2.6  In vitro microglial activation assay 
 Microglial activation was assessed as previously described [121, 195].  Avitene and 
astrocyte-derived ECM suspensions were used to coat 12 mm glass coverslips by adding 50 μL 
to the coverslip surface, allowing them to air dry in a sterile hood, and rinsing them in sterile 1x 
PBS for 45 min in an incubator.  Primary P2 rat microglia were then seeded on control glass 
coverslips or ECM coated samples in a 24-well plate at a density of 8,000 cells/cm2 in 
DMEM/F12 supplemented with 10% FBS.  Microglia morphology was assessed with indirect 
immunohistochemistry for CD68 (ED-1, AbD Serotec, Raleigh, NC, 0.25 μg/mL) and IBA1 
(WAKO, Richmond, VA, 0.5 μg/mL) then counterstained with DAPI (4',6-Diamidino-2-
Phenylindole, Dihydrochloride, Life Technologies, Carlsbad, CA, 10 μM).  Using a 20x objective 
IBA1+ microglia cells were morphologically classified as either ramified or amoeboid as 
previously described [195].  In brief, Ramified cells had 2+ branches that were equal to at least 
0.5 diameter of cell body.  If only 2 branches were present then at least 1 branch had to be 
ramified.  Each field of view was considered a sample (n = 8 for uncoated controls, n = 11 for 
Avitene coated, and n = 12 astrocyte-derived ECM coated).  Cohort means were calculated as a 
percentage of cells that were ramified.  Astrocyte-derived ECM coatings were also seeded with 
primary dorsal root ganglion cells (DRGs) at a density of 20,000 cells/cm2 to assess neuronal 
viability and neurite extension with Calcein AM and NeuroFilament 160 (NF 160), respectively. 
 
2.2.7  Microelectrode arrays 
 Planar 300 μm wide silicon MEAs, identical to those used previously [136, 163], were 
supplied by the Professor Ken Wise, Center for Wireless Integrated Microsystems, at the 
University of Michigan.  To facilitate handling, MEAs were attached to a 0.25 mm diameter 
stainless steel wire with a medical-grade solvent-free ultraviolet-light (UV) curable acrylated 
urethane adhesive (MD-1187-M, Dymax, Torrington, CT).  The MEAs were cleaned by immersion 
in 70% ethanol followed by several rinses in sterile DI water.  Following cleaning, the MEAs were 
sterilized with ethylene oxide (EtO) in the University Hospital Surgical Processing Department 
and were allowed to outgas for at least 48 hr prior to implantation or sterile coating.  Sterile 
packets containing the MEAs remained sealed until the time of implantation or were only opened 
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within the sterile environment (biosafety level 2 hood) for coating application. 
 
2.2.8  Microelectrode array extracellular matrix coatings 
 In order to coat batches of substrates in a reproducible manner a custom dip coating 
apparatus was designed with controlled actuation for optimized insertion and retraction speeds.  
A sterile-filtered, nitrogen jet was used as an air knife to maintain coating uniformity.  Batches of 
planar single-shank silicon MEAs were coated with ECM suspensions.  For both coatings, 10 
insertion and retraction cycles were used.  Following the coating process each MEA was rinsed 
with sterile ultrapure water to neutralize the surface.  The coated devices were then allowed to air 
dry sealed within the sterile environment and remained in that condition until implantation. 
 
2.2.9  Animal surgery 
 All procedures involving animals were approved by the University of Utah Institutional 
Animal Care and Use Committee (IACUC) and similar to those described previously [75, 76, 136, 
163].  Briefly, male Sprague-Dawley rats (10 week old ± 2 weeks, 350 g ± 50 g) were 
anesthetized via inhalation of vaporized 5% isoflurane/oxygen to induce anesthesia and then 
maintained at 2.5% isoflurane/oxygen during the procedure.  During the procedure, animal body 
temperature was regulated (ATC1000, World Precision Instruments, Sarasota, FL).  After 
reaching a full level of anesthesia as assessed by lack of response to a tail/toe pinch, the 
animal’s head was shaved, and the scalp was disinfected with 70% isopropanol and betadine.  
Animals were then transferred to a stereotaxic frame, and a midline incision extending the length 
of the skull was made.  The skin was retracted and the fascia was removed with a scalpel blade.  
The exposed skull was then thoroughly dried with cotton tipped applicators.  A craniotomy was 
then cut with a pneumatically-driven burr under sterile PBS irrigation, with the center of the hole 
positioned above the right hemisphere motor cortex at 0.2 mm rostral of Bregma, and 3 mm 
lateral to Bregma.  Using a stereomicroscope, the exposed Dura was then opened with a 25 G 
needle and deflected to the side to expose the cortical surface.  A custom fabricated polyurethane 
(ST-1085 A/B, BJB Enterprises, Inc., Tustin, CA) grommet was positioned into the craniotomy to 
maintain electrode position over the chronic time point.  The electrode was stereotactically 
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positioned over the affixed grommet’s annular opening.  The electrode was lowered into cortical 
tissue to a depth of 2 mm and UV-curable adhesive was used to bond the electrode to the 
grommet (Fig. 2.2).  A UV lamp (50W, Dymax) was used to cure the UV curable adhesive.  
Following these procedures, the skin was closed over the fixed electrode with suture (Vicryl Plus, 
Ethicon, Somerville, NJ).  An antibiotic ointment, Neosporin (Johnson & Johnson, New 
Brunswick, NJ), was applied to the closed incision.  The animals were allowed to recover in 
individual cages under observation.  Sutures were monitored and those which were not removed 
by the animal during normal grooming were removed after approximately 2 weeks [68].  Each 
animal received a single implant in the right motor cortex that was either coated with ECM or an 
uncoated control. 
 
2.2.10  Euthanasia and tissue preparation 
 Animals were deeply anesthetized with 5% isoflurane and transcardially perfused with 
PBS followed by 4% paraformaldehyde in PBS.  For astrocyte-derived ECM coated and its 
control cohort, microelectrodes were carefully dissected from brain tissue using microdissection 
forceps under stereoscopic observation.  Immunolabeling and imaging of the MEA surface 
showed little cell adhesion (data not shown).  For Avitene coated MEAs and its control cohort, 
MEAs were left in brain tissue.  Retrieved brains were postfixed with 4% paraformaldehyde for 24 
hr at 4°C.  Brains were then equilibrated in 30% sucrose.  Following equilibration, brains were 
embedded in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, NC), serially 
sectioned in the horizontal plane (tangent to the cortical surface and perpendicular to the 
electrode tract) at 30 μm thickness with a cryostat (Leica Microsystems, Bannockburn, IL). 
 
2.2.11  Histology 
 Tissue sections from Avitene- and astrocyte-derived ECM coating cohorts were 
processed in batch with sections from uncoated control cohorts.  Horizontal sections were 
processed using indirect immunohistochemistry and primary antibodies against CD68 (ED-1, AbD 
Serotec, Raleigh, NC, 0.25 μg/mL) to assess activated microglia/macrophages; GFAP (DAKO, 
Carpinteria, CA, 2.9 μg/mL) to localize intermediate filaments of astrocytes; rat IgG (Southern 
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Biotech, Birmingham, AL, 0.5 μg/mL) as an indicator of BBB permeability; and NeuN 
(Chemicon/Millipore, Billerica, MA, 2.0 μg/mL) to label neuronal cell bodies [72, 136, 190].  
Antibodies were diluted in a blocking solution consisting of 4% (v/v) goat serum (Invitrogen, 
Carlsbad, CA), 0.5% (v/v) Triton-X 100, and 0.1% (w/v) sodium azide.  Free-floating (0.5 mL 
solution in 24-well plates) tissue sections were batch treated for 1 hr in blocking solution at room 
temperature, followed by incubation with primary antibodies for 18 hr at room temperature.  After 
3 washes in PBS at room temperature to remove excess antibody (1 h/wash), appropriate 
fluorescently labeled secondary antibodies (Invitrogen, Carlsbad, CA) were applied in block for 18 
hr at room temperature, followed by 3 washes in PBS (1 h/wash).  During the secondary antibody 
incubation, sections were isolated from light to prevent photobleaching.  All sections were also 
counterstained with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride, Life Technologies, 
Carlsbad, CA, 10 μM) to identify cell nuclei.  Tissue sections were mounted on microscope slides 
with Fluormount-G (Southern Biotech, Birmingham, AL) and cover-slipped [72]. 
 
2.2.12  Quantitative image analyses 
 Fluorescent images of tissue sections from layers IV-VI of the cortex were captured in 
batch with a Coolsnap digital camera on an Eclipse E600 microscope (Nikon) with a 10x air 
objective, using identical exposure times between coated and uncoated control MEAs.  Imaging 
conditions were optimized for each immunomarker.  All fluorescent images were light-field 
corrected [5].  The staining intensity for each immunomarker was quantified using a custom 
LabView-based image analysis program (National Instruments, Austin, TX) as previously 
described [72, 73, 136, 163, 240].  In brief, fluorescent intensity as a function of distance from the 
implant site was extracted using an array of line profiles spanning the implant site.  At each point 
along the lines, an anti-alias pixel extraction algorithm was used to derive the pixel intensity of the 
line profile arrays in each section.  The intensity profiles for a given immunomarker from each 
layer, IV-VI, were normalized to background levels.  In order to quantify changes in neuronal cell 
body distribution, the numbers of NeuN/DAPI+ cells were manually counted in discrete bins every 
50 μm from the device interface.  The number of neuronal nuclei per bin were then divided by the 
bin area to determine the average neuronal nuclear density as an estimate of the number of 
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neuronal cell bodies surrounding the device.  Neuronal density was then normalized to 
background levels.  Representative images were taken on a confocal microscope (Fluoview 
FV1000, Olympus America Inc., Center Valley, PA) with either a 10x air or 60x water immersion 
objective.  Representative images were arithmetically chosen from animals which best 
represented the cohort means. 
 
2.2.13  Statistics 
 For the Lee-White clotting time and the microglia activation assay, cohorts were 
compared using one-way ANOVAs and Tukey post-hoc analysis by means of an SPSS software 
package (IBM, Somers NY), with p < 0.05 considered as a significant difference.  All data are 
mean and standard error of the mean. 
 For the quantitative image analysis, to minimize variability and develop a more accurate 
cohort mean, discrete points were compared against each other as a function of distance from 
the biotic/abiotic interface with an outlier analysis (1.5 * interquartile range).  Outlying points were 
automatically removed.  The outlier analysis was run three consecutive times on each cohort’s 
rostral and caudal profiles.  In some cases the automatic outlier removal resulted in an animal 
being removed from the cohort, which is reflected in the quantification figure legends.  Following 
outlier removal, section profiles were averaged to obtain an average intensity profile for a given 
animal.  The average intensity profile for a given animal was then averaged with other animal 
profiles receiving the same type of implant to obtain an average intensity profile for each cohort.  
The average area under the curve of each cohort's intensity profile for each immunomarker as 
well as the average neuronal nuclear density at 50 mm intervals from the device interface 
compared uncoated controls with each ECM coated cohort, Avitene n = 7 and astrocyte-derived 
ECM n = 6, using a Student’s t-test with p < 0.05 considered as a significant difference.  All data 










2.3  Results 
 
2.3.1  Characterization of ECM 
 The Avitene MCH Flour was white and cotton- or powder-like in appearance and had an 
innate cohesiveness that aided manipulation (Fig. 2.3).  Similar to Avitene and ECM derived from 
other sources, the ECM derived from astrocytes was a white, insoluble, solid biomaterial (Fig. 
2.4).  Following decellularization no cell nuclei or cytoskeletal structures were found within the 
astrocyte-derived ECM.  Furthermore, all ECM components investigated with 
immunohistochemistry and MS/MS remained following decellularization. 
 Purification of the microfibrillar collagen in Avitene is detailed in several patents.  The 
general process includes enzymatic-treatment (elastases, ficin, etc.) of sliced bovine dermis, 
alkaline borohydride washes, and a 1% salt solution to remove impurities, and finally precipitated 
by increasing the pH results in a purified collagen [241, 242].  Proteomic analysis of the astrocyte-
derived ECM with MS/MS (Table 2.1) identified a variety of extracellular proteoglycans and 
glycoproteins.  Example proteins and their influence on wound healing are described in Table 2.1.  
Astrocyte-derived ECM samples were processed using indirect immunocytochemistry for various 
ECM components found in the CNS.  The astrocyte-derived ECM was immunoreactive for 
antibodies against fibronectin, laminin, and chondroitin sulfate gycosoaminoglycans (CS GAGs).  
Representative fluorescent images of these ECM components found in astrocyte-derived material 
are shown in Fig. 2.4B-D.  Avitene coatings on the other hand showed no specific 
immunoreactivity for the same antibody fibronectin, laminin, and chondroitin sulfate 
gycosoaminoglycans (CS GAGs), but were immunoreactive for antibodies against collagen type I. 
 Lee-White clotting time was assessed for each of the coatings in 1.5 mL plastic conical 
tubes.  Both the Avitene and astrocyte-derived ECM coatings had a significantly shorter time-to-
clot, as compared with uncoated controls (Fig. 2.5A-B).  There was no difference in the clotting 
time between the 2 ECM coatings. 
 
2.3.2  In vitro microglial activation assay 
 The phenotype of microglia cultured on glass, Avitene, and astrocyte-derived ECM was 
quantified following Iba-1 immunolabeling.  Fig. 2.5C-D shows the representative microglial 
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morphology when cultured on glass and astrocyte-derived ECM coatings in the presence of 
serum.  Similar to studies examining microglial morphology on fixed astrocyte monolayers, a 
significant number of microglia cultured on the astrocyte-derived ECM coating showed a more 
ramified, resting phenotype (Fig. 2.5D) than those cultured on glass.  There were few ramified 
microglia on the Avitene coating, which was not statistically different than uncoated controls. 
 Cytocompatibilty studies also showed the astrocyte-derived ECM to be nontoxic and 
adhesive to primary CNS cells.  NF160 immunolabeling of P1 rat primary DRGs cultivated for 
48 hr on astrocyte-derived ECM showed facilitation of neurite outgrowth (data not shown).  
Furthermore, Calcein AM viability staining of the DRGs showed no signs that the astrocyte-
derived ECM was cytotoxic (data not shown). 
 
2.3.3  Coating morphology and uniformity 
 Compared to uncoated controls both the Avitene and astrocyte-derived ECM coating 
were evident under stereoscopic microscopy following 10 cycles of dip coating (Fig. 2.6).  
Nitrogen jets aided in the uniformity of the coating, in their absence the coating appeared 
heterogeneous and thicker near the tip due to droplet formation.  Immunolabeling of collagen type 
I following Avitene dip coating showed evidence of collagen microfibrils interwoven on the 300 μm 
wide MEA faces (Fig. 2.6D-E).  The thickness of the coating visualized by stereomicroscopy 
appeared less than 1 μm on average.  There was no evident change in either of the coatings 
dimensions when hydrated. 
 
2.3.4  Immunohistological quantification of the foreign body response 
 GFAP was greatest along the 300 μm face of the planar silicon MEA, as opposed to the 
12 μm edges.  In comparison to uncoated controls, quantitative image analysis (Fig. 2.7) showed 
a significant reduction in GFAP immunoreactivity surrounding astrocyte-derived ECM coated 
MEAs within the presumptive recording zone.  There was no significant difference in GFAP 
immunoreactivity between uncoated controls and Avitene coated MEAs.  Higher magnification 
images (Fig. 2.8) indicated that astrocyte intermediate filaments appeared similar in thickness 
and distribution to those in astrocytes located in normal cortex when compared to either uncoated 
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or Avitene coated MEAs.  This was particularly pronounced when viewed by eye using 
stereoscopic magnification. 
 In comparison to uncoated controls, quantitative image analysis (Fig. 2.9) showed a 
significant increase in IgG immunoreactivity surrounding the Avitene coated MEA within the 
presumptive recording zone.  There was no significant difference in IgG immunoreactivity 
between uncoated controls and astrocyte-derived ECM coated MEAs.  Additionally, although IgG 
immunoreactivity was elevated surrounding all implants it was rarely symmetrically distributed  
around the electrode in horizontal sections and was higher surrounding blood vessels. 
   In horizontal sections, CD68 immunoreactivity was observed surrounding all implants.  
CD68 immunoreactivity returned to background levels beyond 100 μm for all cohorts.  In 
comparison to uncoated controls, there was (Fig. 2.10) no significant difference in CD68 
immunoreactivity surrounding astrocyte-derived ECM coated or Avitene coated MEAs. 
 In comparison to uncoated controls, there was no significant difference in the spatial 
distribution of NeuN immunoreactivity between the cohorts (Fig. 2.11). 
 
2.4  Discussion 
 
 Using a simple model system, it was shown that an allogeneic ECM coating developed 
from rat cortical astrocytes in vitro, with hemostatic and immunomodulatory properties, was 
sufficient to lower astrogliosis surrounding a planar silicon MEA 8 weeks after implantation.  In 
contrast, it was shown that a xenogenic hemostatic coating developed from FDA-approved 
Avitene™ MCH was not sufficient to lower any aspect of the FBR 8 weeks after implantation. 
 GFAP labels the cytoskeleton of astrocytes and is used as a marker of astrocyte 
hypertrophy and astrogliosis.  It has been frequently used as a biomarker of tissue reactivity [76].  
In this study, a significant decrease was observed in the spatial distribution and intensity of GFAP 
immunoreactivity surrounding the astrocyte-derived ECM coated as MEAs compared to uncoated 
or Avitene™ coated MEAs (Fig. 2.7).  The difference was particularly striking when viewed by eye 
with a binocular, stereomicroscope where the thickness of the majority of astrocyte intermediate 
filaments near the astrocyte-derived ECM coated interface more closely resembled that observed 
in unimplanted cortex at the same cortical level.  The mechanism driving this difference likely 
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occurred acutely as the level of gliosis surrounding similar devices does not progress following 
the first 2 weeks of implantation and is observed at chronic time points following stab wound 
injuries in which the MEA was retrieved immediately following insertion [73, 76].  In cases of stab 
wounds made with a device or resulting from surgery or trauma the neuroinflammatory 
biomarkers (CD68, IgG) eventually resolve, while the astroglial scar remains [243]. 
 IgG is an antibody present in blood and generally is not present in the extracellular space 
of brain tissue due to the blood brain barrier (BBB), which restricts its presence to the vascular 
lumen except in cases of neuroinflammation, following injury or surrounding chronically implanted 
biomedical devices.  BBB leakiness, a hallmark of neuroinflammation, is signaled by the presence 
of IgG immunoreactivity in the extracellular space of brain tissue [124].  An unexpected finding in 
the current study was that the immunoreactivity for IgG was elevated surrounding the Avitene™ 
coated MEAs compared to the other cohorts.  Given the presence of phagocytic macrophages in 
the acute phase of the FBR it is doubtful that the increased IgG represents a remnant from the 
initial hemorrhage that followed implantation.  Studies on provisional matrix formation and its 
turnover suggest that it would be removed by 8 weeks [244].  Given the small quantity of material 
used for coating it also seems unlikely that the original ECM coatings would persist over the 8-
week indwelling period [245].  It is, therefore, unclear why the observed IgG surrounding the 
Avitene™ coated implants was more compared to the other cohorts. 
 CD68 labels a lysosomal-associated membrane glycoprotein in macrophages and in 
tissue specific macrophages like microglia.  CD68 is upregulated in areas of neuroinflammation, 
thus, it is commonly used as an indicator of macrophage/microglial activation [76, 132].  Neither 
the Avitene™ nor the astrocyte-derived ECM coatings had an influence on CD68 compared to 
uncoated controls.  This suggests that neither coating was effective in modulating late stage or 
chronic inflammatory sequela of the FBR.  A possible explanation for this could be that such 
protein-based coatings were degraded soon after implantation and only have an impact on early 
phase downstream events like astrogliosis. 
 NeuN labels the nucleus of neurons and can be used to quantify the density of neurons.  
Similar to the CD68 results, neither the Avitene™ nor the astrocyte-derived ECM coatings had an 
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influence on NeuN spatial density compared to uncoated controls.  The loss of neuronal cell 
bodies was similar to previous reports from our lab and others that show a decrease of 
approximately 50% within the recording zone, which did not change over time for simple single-
shank devices that cause a minimal penetrating injury [73, 136, 163].  One caveat of neuronal 
density is that it is not necessarily an indicator of neuronal activity.  Neuron excitability is 
influenced by changes in the ionic balance of the extracellular milieu which is disturbed BBB 
leakiness.  Thus, while neuronal density may have been similar after use of the ECM coatings the 
increase in BBB leakiness surrounding the Avitene™ coated MEA may affect recording 
performance [73, 130].  It will be interesting to see how such coatings influence neuronal density 
and macrophage activation in the FBR of more clinically relevant higher density multi-shank 
MEAs, such as the UEA, where the amount of vascular damage following implantation is orders 
of magnitude greater than that caused by single-shank MEA designs. 
 The decrease in astrogliosis surrounding the astrocyte-derived ECM is perhaps the most 
important observation from this study.  This is important as the level of astrogliosis has been 
correlated with single unit recording performance [68].  Thus, the impact of a decrease in GFAP 
surrounding astrocyte-derived ECM coatings may potentially increase the functional longevity of 
devices implanted in the brain.  Interestingly, a prior study from our group using an identical 
uncoated control and model system showed that by reducing surface area with a lattice 
architecture, which maintained the same penetration profile and initial injury, there was a 
reduction in chronic macrophage activation, BBB leakiness, and an increase in neuronal density 
at 8 weeks [163].  However, the decrease in surface area had no influence on the degree of 
astrogliosis at 8 weeks.  Combining results from the ECM coating study with those from the 
surface area study, given their identical controls and analysis technique, indicates a divergent 
pathway in the development of the FBR where constitutive properties, such as surface area, have 
a more prominent impact on the chronic levels of macrophage activation, BBB leakiness, and 
neuronal density while bioactive coatings, such as the astrocyte-derived ECM, have a more 
prominent impact on the chronic level of astrogliosis. 
 The results and deductions from this study agree with reports of other groups which have 
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shown that anti-inflammatory drug eluting and single protein coatings are able to influence GFAP 
intensity [148, 175-177].  One unique difference, to the best of my knowledge, is the Avitene™ 
coating being the first protein coating applied to a recording MEA that did not show a significant 
decrease in any biomarker associated with the FBR. 
 An area for future consideration is the extensive implantation induced injury, as 
demonstrated by a stab wound model, observed following implantation of the Utah Electrode 
Array (UEA), a high density, multi-shank silicon MEA.  Implantation induces a prominent lesion 
with extensive tissue loss that looks like an inverted pyramid with the largest area of the lesion 
occurring below the base of the UEA [68].  Lesions of this nature, which resemble lesions from 
stroke injury are not observed following stab wounds with single-shank, silicon MEAs likely due to 
their small penetrating profile and the lesser amount of vasculature damage following 
implantation.  It would therefore be interesting to see whether such hemostatic coatings would 
lower the lesion volume that accompanies the implantation of a higher density MEA. 
 Another future question to investigate at greater depth is why the two ECM coatings 
performed differently.  The hemostatic ability of Avitene™ is well documented in research and 
clinically [185, 233].  Immunohistochemical and proteomic analysis of the astrocyte-derived ECM 
revealed a number of proteins which have varying influences on biological processes.  The 
collagens identified, VI and XII, both possess hemostatic potential, which likely is the source of 
the hemostatic ability observed in the clotting assays (Fig. 2) [180].  While both of the ECM 
coatings examined here had equivalent hemostatic properties only the allogeneic astrocyte-
derived hemostat showed influence in the microglial activation assay (Fig. 2C-E).  An unknown is 
what specific contribution the astrocyte-derived ECM’s species- and tissue-specificity may have 
had, as both characteristics have been indicated as contributors to tissue-appropriate remodeling 
[246, 247].  This is compounded by the antiscarring and anti-inflammatory aspects of the 
astrocyte-derived ECM proteins found in the proteomic analysis and detailed in Table 2.1.  
Importantly, previous studies have shown that each of the identified ECM components are found 
in brain tissue and are produced by astrocytes [248-250].  This suggests that such coatings may 
have decreased the neuroinflammatory components of the FBR, however, this influence may be 
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limited to the acute inflammatory phase. 
 
2.5  Conclusions 
 
 The results of this study show that ECM coatings derived from different genetic 
backgrounds differentially affect the FBR to single-shank, silicon MEAs.  From a general 
biomedical device perspective, this study provides the first evidence that an allogeneic in vitro 
cell-derived ECM coating is able to decrease the degree of astrogliosis surrounding a chronically 
implanted single-shank MEA, presumably due to immunomodulatory effects on acute microglial 
activation.  In concert with previous work on constitutive modification, results support the concept 
of divergent pathways within the FBR and decreasing the overall FBR to further improve 
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Fig. 2.1.  Cell-derived biomaterial process schematic.  (A) Representative SEM of sacrificial 
PU scaffold.  Scale bar 1 mm.  The cell-derived material is develop through seeding cells 
onto the (B) porous PU scaffold.  This dissertation’s cell type of focus was primary rat 
astrocytes which (C) expand and secrete proteins within the pores of the PU scaffold.  The 
PU scaffold is then degraded with multiple rinses of DMAC which results in (D) a cell-
derived material which is then further processed with detergent and enzymatic 
decellularization techniques and/or lyophilized.  (B-D) For scale, scaffold width is 2 mm. 
(A) Adapted by permission from Elsevier: Biomaterials, K. Webb, W. Li, R. W. Hitchcock, R. 
M. Smeal, S. D. Gray, P. A. Tresco, Comparison of human fibroblast ECM-related gene 
expression on elastic three-dimensional substrates relative to two-dimensional films of the 
same material, Biomaterials 24 (2003) 4681-4690. http://dx.doi.org/10.1016/s0142-




Fig. 2.2  Rat cortical implantation schematic.  (A) Side profile CAD drawing of a mid-
sagittal section of rat head showing approximate location of implanted silicon MEA and 
anchoring (B) polyurethane grommet.  All MEAs were lowered stereotactically to a 
controlled depth of 2 mm below the surface of the cortex, and attached to a soft 
polyurethane grommet (orange) using a UV-curable adhesive (cyan) as shown.  (C) Top 
view of stereotactic implantation position (+) in the right motor cortex at coordinates +0.2 
mm Bregma, 3 mm lateral, and 2 mm depth. 
(A) Adapted by permission from Elsevier: Biomaterials, B. D. Winslow, P. A. Tresco, 
Quantitative analysis of the tissue response to chronically implanted microwire electrodes 
in rat cortex, Biomaterials 31 (2010) 1558-1567. 




Fig. 2.3.  Avitene MCH Flour dry macroscopic appearance, suspension, and TEM 
characterization.  (A) Dry, sterile, Avitene™ MCH Flour.  (B) Avitene suspended in 0.25 M at 
1 mg/mL following stirring at room temperature for 24 hr and filtering with a nylon 70 μm 
cell strainer.  (C) TEM image of Avitene morphology, displaying characteristic periodicity 
natural collagen due to the triple-helix structure.  Scale bar 0.5 μm.  TEM image courtesy of 





Fig. 2.4.  Astrocyte-derived ECM scaffold and immunolabeled proteins.  (A) Representative 
light micrograph of an astrocyte ECM scaffold after dissolution of the synthetic 
polyurethane foam and lyophilization.  Scale bar 2 mm.  Immunohistochemical labeling of 
astrocyte secreted ECM proteins (B) fibronectin, (C) laminin, and (D) chondroitin sulfate 




Fig. 2.5.  In vitro hemostatic and immunomodulatory characterization of ECM.  Average 
Lee-White clotting time for (A) recalcified, citrated-whole blood placed in control 
centrifuge tubes or tubes coated with Avitene or astrocyte-derived ECM.  (B) Both ECM 
coatings showed a similar ability to promote blood clotting compared to the uncoated 
control.  (*) denotes significant difference with p<0.05, compared to uncoated control.  
Cytocompatibility studies showed the cell-derived material to be nontoxic to primary CNS 
cells.  Representative P1 rat primary microglial morphology cultured on (C) uncoated 
glass or (D) an astrocyte-derived ECM coating.  Scale bar 25 μm.  (E) Quantification of 
microglia morphology on uncoated glass, Avitene and astrocyte-derived ECM coated 
coverslips, shown as percent ramified.  Ramified cells had 2+ branches that were equal to 
at least 0.5 diameter of cell body.  If only 2 branches were present then at least 1 branch 
had to be ramified.  Coverslips coated with astrocyte-derived ECM had a significantly 
increased percentage of ramified microglia on the surface.  (**) denotes significant 
difference with p < 0.05, compared to uncoated control and Avitene coated.  Data shown 




Fig. 2.6.  Dip coating apparatus with astrocyte-derived ECM and Avitene coated MEAs.  
MEAs were dip coated in a (A) sterile environment containing a pneumatic dip coater, 
sterile filter nitrogen jets (to aid in layer adsorption and uniformity), and a protein 
suspension composed of Avitene Microfibrillar Collagen Hemostat or astrocyte-derived 
ECM.  (B) A cleaned and sterilized silicon MEA.  (C) Stereoscopic light micrograph of an 
astrocyte-derived ECM coated MEA.  (D) Avitene coated MEA immunolabeled for collagen 
type I.  Scale bar 100 μm.  (E) A high magnification image of Avitene coated MEA 




Fig. 2.7.  Representative images of in vivo GFAP immunoreactivity and quantification. 
(A and B) Representative images of horizontal sections showing immunoreactivity for 
GFAP (astrocytes) surrounding (A) uncoated MEAs as compared with (B) Avitene coated 
MEAs.  (C and D) Representative GFAP immunoreactivity surrounding (C) uncoated MEAs 
as compared with (D) astrocyte-derived ECM coated MEAs.  Scale bar 100 μm.  (E and F) 
Average immunofluorescent profiles comparing uncoated and coated cohorts.  (G and H) 
GFAP immunofluorescence binned as a function of distance from the biotic/abiotic 
interface in 50 μm bins from 0 to 400 μm.  (G) No significant differences were observed 
between uncoated controls and Avitene coated MEAs.  8-week time point, n = 6.  (H) 
Compared to uncoated controls, MEAs coated with astrocyte-derived ECM had 
significantly reduced GFAP immunoreactivity within the presumptive recording zone (first 
50 μm from the interface).  8-week time point, n = 5.  (*) denotes significant difference with 




Fig. 2.8.  Representative GFAP immunoreactivity at high magnification.  GFAP 
immunolabeling observed in (A) background tissue (contralateral to implant), (B) at an 
uncoated interface, and (C) at an astrocyte ECM coated interface.  (A) GFAP 
immunolabeling of a background astrocyte.  Astrocyte end feet (white arrows) wrapping a 
blood vessel in the bottom portion of the image.  (B) The intensity of GFAP 
immunoreactivity adjacent to an uncoated control interface is exponentially higher than 
background levels.  (C) The intensity of GFAP immunoreactivity adjacent to an astrocyte 
ECM coated interface is higher than background but significantly lower than uncoated 
controls.  All sections were batch stained, imaged and processed with identical settings 
and were from animals that arithmetically represented the mean cohort response (8-week 




Fig. 2.9.  Representative images of in vivo IgG immunoreactivity and quantification. 
(A and B) Representative images of horizontal sections showing immunoreactivity for IgG 
(blood products in brain parenchyma) surrounding (A) uncoated MEAs as compared with 
(B) Avitene coated.  (C and D) Representative IgG immunoreactivity surrounding (C) 
uncoated MEAs as compared with (D) astrocyte-derived ECM coated MEAs.  Scale bar 100 
μm.  (E and F) Average immunofluorescent profiles comparing uncoated and coated 
cohorts.  (G and H) IgG immunofluorescence binned as a function of distance from the 
biotic/abiotic interface in 50 μm bins from 0 to 400 μm.  (G) Compared to uncoated 
controls, MEAs coated with Avitene had significantly increased IgG immunoreactivity 
within the presumptive recording zone (first 50 μm from the interface).  8-week time point, 
n = 6.  (H) No significant differences were observed between uncoated controls and 
astrocyte ECM coated MEAs.  8-week time point, n = 5.  (*) denotes significant difference 




Fig. 2.10.  Representative images of in vivo CD68 immunoreactivity and quantification. 
(A and B) Representative images of horizontal sections showing immunoreactivity for 
CD68 (activated macrophages) surrounding (A) uncoated MEAs as compared with (B) 
Avitene coated MEAs.  (C and D) Representative CD68 immunoreactivity surrounding (C) 
uncoated MEAs as compared with (D) astrocyte-derived ECM coated MEAs.  Scale bar 100 
μm.  (E and H) CD68 average immunofluorescent profiles for each cohort and 
immunofluorescence binned as a function of distance from the biotic/abiotic interface in 
50 μm bins from 0 to 100 μm.  No significant differences were observed between uncoated 
controls and astrocyte ECM or Avitene coated microelectrodes.  8-week time point, n = 5 




Fig. 2.11.  Representative images of in vivo NeuN immunoreactivity and quantification. 
(A and B) Representative images of horizontal sections showing immunoreactivity for 
NeuN (neuronal nuclei) surrounding (A) uncoated MEAs as compared with (B) Avitene 
coated.  (C and D) Representative NeuN immunoreactivity surrounding (C) uncoated MEAs 
as compared with (D) astrocyte-derived ECM coated MEAs.  Scale bar 100 μm.  (E-F) NeuN 
density for each cohort binned as a function of distance from the biotic/abiotic interface in 
50 μm bins from 0 to 400 μm.  No significant differences were observed between uncoated 
controls and (E) astrocyte coated MEAs.  Similarly, no significant differences were 
observed between uncoated controls and astrocyte-derived ECM coated MEAs.  8-week 
time point, n = 5 for all cohorts.  Data shown as mean and standard error of the mean.  
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Table 2.1.  Example proteins found in astrocyte-derived ECM with MS/MS in addition to 
those identified with IHC (Fig. 2.4). 
 
Component Description and Role(s) In Wound Healing Refs 
Collagen VI A beaded filament forming collagen that promotes 
platelet adhesion and thrombosis under low shear 
conditions.  Binding site for Von Willebrand factor. 
[180, 252, 253] 
Collagen XII A fibril associated proteoglycan important for 
proper matrix assembly and mechanotransduction.  
Also promotes platelet adhesion and thrombosis 
under low shear conditions. 
[180, 254] 
Tenascin N and W Promotes neurite outgrowth and pathfinding.  
Regulates inflammatory cell migration and activity.  
Promotes glial proliferation and differentiation. 
[255, 256] 
Perlecan A basement membrane-specific heparan sulfate 
proteoglycan participating in the blood brain 
barrier.  Also promotes tissue regeneration by 
activating various growth factors. 
[257-259] 
Thromobospondin-1 An adhesive glycoprotein that promotes platelet 
adhesion.  Binds to fibrinogen, fibronectin, laminin, 
and various collagens.  Inhibiting neoangiogenesis.  
Major activator of TGFβ-1. 
[260-262] 
Fetuin-A Plasma-binding protein that is heavily expressed 
during early brain development.  Plays anti-
inflammatory and neuroprotective roles in a variety 
of neurodegenerative disease and injury models.  
Fetuin can bind TGF-β1 and prevent TGF-β1-
mediated signaling and fibrosis. 
[250, 263, 264] 
Neural Cell Adhesion 
Molecule (NCAM) 1 
Cell-cell and Cell-matrix adhesion protein involved 
in CNS development, synaptic plasticity, and 







THE FOREIGN BODY RESPONSE TO HEADSTAGE 
 
COMPONENTS USED FOR DEVICE FIXATION 
 
IN CHRONIC CNS STUDIES IN RATS 
 
 
 The format of this chapter is based on the Biomaterials journal.  Authors of the prepared 
manuscript include Robert S. Oakes, Dr. Michael B. Christensen, and Dr. Patrick A. Tresco. 
 
3.1  Introduction 
 
 Neural recording devices that utilize cortically-implanted microelectrode arrays (MEAs) 
have become an invaluable tool for extending the understanding of neural circuitry [134, 269, 270].  
In clinically relevant applications, cortically-implanted recording MEAs enable volitional control of 
various brain-machine interfaces (i.e., computer or robotic limb) with high resolution [43, 271].  
However, variable functional reliability and inconsistent longevity are major hurdles that have 
limited the clinical translation of this promising technology [49, 60, 144, 272].  These shortcomings 
have, at least in part, been attributed to the foreign body response (FBR) at the electrode-brain 
tissue interface.  The primary characteristics of which include persistent macrophage activation, 
astrogliosis, decreases in neuronal density, and BBB leakiness [76, 124, 132, 199].  To improve 
the biocompatibility of this type of device it is necessary to understand the causes of the FBR and 
to minimize its influence on recording performance [124, 136, 137]. 
 While significant attention has been directed towards studying the FBR to different types 
of MEAs [70, 73], little attention has been directed to studying the FBR associated with the 
components used to secure such devices to the skull during chronic use, which include adhesives, 
acrylic cements and bone screws [58, 70, 197, 198].  Bone screws are of particular interest as they 
can penetrate the skull and make contact with the meninges and/or brain tissue. 
In this study, using immunohistochemical approaches the FBR to various components used to 
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anchor recording devices to the rat skull was analyzed over a long indwelling period.  The results 
indicate that headstage components add to the neuroinflammatory burden of such devices and 
may affect brain function at sites millimeters away from the implanted electrode. 
 
3.2  Methods 
 
3.2.1  Microelectrodes and headstage components 
 Several types of MEA fixation approaches were analyzed.  Two types were in situ 
fabricated, and consisted of stainless steel self-tapping bone screws (#19010-00, 1.17 mm 
diameter, 18/8 grade SS, Fine Science Tools (FST), Foster City, CA), Kwik-Cast silicon elastomer 
(World Precision Instruments, Sarasota, FL), and either a medical-grade solvent-free ultraviolet-
light (UV) curable acrylated urethane adhesive (MD-1187-M, Dymax, Torrington, CT) or a 
traditional two part acrylic cement.  Another headstage type used a shear-resistant precast 
polyurethane elastomer (ST-1085 A/B, BJB Enterprises, Inc., Tustin, CA), Kwik-Cast silicon 
elastomer, and larger stainless steel screws (#B-MX-172-3, 1.85 mm diameter, 18/8 grade SS, 
Small Parts Inc., Miami Lakes, FL).  All components were cleaned and sterilized with 70% 
isopropyl alcohol prior to implantation.  Two types of recording devices were used including a 4 x 
4 Utah Electrode Array (Blackrock Microsystems, Salt Lake City, UT) consisting of sixteen boron-
doped silicon tapered shanks (1000 μm length, ~80 μm base thickness, 400 μm interelectrode 
spacing) or a lattice style or solid style Michigan planar array, also made of silicon.  The recording 
devices were sterilized with ethylene oxide (EtO) by the University Hospital Surgical Processing 
Department and were allowed to outgas for at least 48 hr prior to implantation.  Sterile packets 
containing the recording devices remained sealed until the time of implantation. 
 
3.2.2  Animal surgery 
 All procedures involving animals were conducted in accordance with the University of 
Utah Institutional Animal Care and Use Committee (IACUC).  Adult male Sprague Dawley rats 
(young:  10 weeks old ± 2 weeks and 325g ± 75g, n = 19; and older adult: 75 weeks old ± 2 
weeks and 850g ± 75g, n = 19) were anesthetized via inhalation of vaporized 5% 
isoflurane/oxygen to induce anesthesia and then maintained at 2.5% isoflurane/oxygen during the 
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procedure.  During the procedure, animal body temperature was regulated (ATC1000, World 
Precision Instruments, Sarasota, FL).  After reaching a full level of anesthesia as assessed by 
lack of response to a tail/toe pinch, the animal’s head was shaved, and the scalp was disinfected 
with 70% isopropanol and butadiene.  Animals were then transferred to a stereotaxic frame, and 
a midline incision extending the length of the skull was made.  The skin was retracted and the 
fascia was removed with a scalpel blade.  The exposed skull was then thoroughly dried with 
cotton tipped applicators.  Pilot holes for screws were made using a pneumatically-driven 
diamond micro burr.  Screws are then turned into the skull with a handheld screw driver.  For the 
in situ fabricated headstage (Fig. 3.1), four screws were placed in the parietal bone near the 
temporal ridge [198].  Two of the screws were placed contralateral to the electrode with the other 
two being placed ipsilateral, one anterior and one posterior to the planned electrode position.  A 
craniotomy was then cut with a pneumatically-driven burr under sterile PBS irrigation, with the 
center of the hole positioned above the right hemisphere motor cortex at 0.2 mm forward of 
Bregma, and 3 mm lateral to Bregma.  To measure skull thickness the bone that was removed 
was rinsed with PBS and measured with calipers.  Using a stereomicroscope, the exposed Dura 
was then opened with a 25G needle and deflected to the side to expose the cortical surface.  The 
electrode was stereotactically positioned over the craniotomy.  The MEA was lowered into cortical 
tissue, Kwik-Cast was then applied to cover the implanted MEA and fill the craniotomy level with 
the skull surface.  For the in situ fabricated headstage, UV-curable adhesive or traditional acrylic 
cement was used to encapsulate the electrical connector and screws.  A UV lamp (50W, Dymax) 
was used to cure the UV curable adhesive during the deposition process, while the acrylic 
cement was allowed to air dry and cure.  For the prefabricated headstage, MEA positioning and 
implantation was the same as described with the exception that only two screws were used to 
secure the headstage through pilot holes in the prefabricated polyurethane headstage.  No UV-
curable adhesive or cement solvent was used with these implants.  The two screw locations were 
in the parietal bones contralateral and posterior to the electrode, respectively.  Following these 
procedures, the skin was closed as needed around the headstage with suture, leaving the 
electrical connector percutaneously exposed.  An antibiotic ointment, Neosporin (Johnson & 
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Johnson, New Brunswick, NJ), was applied around the headstage and sutures.  The animals 
were allowed to recover in individual cages under observation.  When sutures were required they 
were removed approximately a week after surgery [68]. 
 
3.2.3  Euthanasia and tissue preparation 
 Animals were deeply anesthetized with 5% isoflurane and transcardially perfused with 
PBS followed by 4% paraformaldehyde in PBS.  Following perfusion fixation, intact neural 
interfaces (the headstage, bone screws, and wires attached to the skull) and brains were carefully 
dissected from tissue using microdissection forceps.  Retrieved brains were postfixed with 4% 
paraformaldehyde for 24 hr at 4°C.  Brains were then equilibrated in 30% sucrose.  Following 
equilibration, brains were embedded in Tissue Freezing Medium (Triangle Biomedical Sciences, 
Durham, NC), serially sectioned in the horizontal or coronal plane at 30 μm thickness with a 
cryostat (Leica Microsystems, Bannockburn, IL). 
 
3.2.4  Immunohistological explanted device surface analyses 
 Explanted tissue and components including the skull, headstage, bone screws, wires, 
and MEAs were imaged (SMZ800 stereoscope, Nikon Instruments Inc., Melville, NY; Coolsnap 
digital camera, Protometrics, Tucson, AZ; VHX-5000, Keyence, Itasca, IL) then immunolabeled 
with CD68 (ED-1, AbD Serotec, Raleigh, NC, 0.25 μg/mL) and IBA1 (WAKO, Richmond, VA, 0.5 
μg/mL), then counterstained with DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride, Life 
Technologies, Carlsbad, CA, 10 μM) to evaluate the presence of surface-adherent, activated 
macrophages as previously described [73].  In brief, antibodies were diluted in a blocking solution 
consisting of 4% (v/v) goat serum (Invitrogen, Carlsbad, CA), 0.5% (v/v) Triton-X 100, and 0.1% 
(w/v) sodium azide.  Components were first incubated with blocking solution for 1 hr then with 
primary antibody for 18 hr at room temperature.  They were then washed with PBS three times at 
room temperature to remove excess antibody (1 hr / wash).  Then appropriate fluorescently 
labeled secondary antibodies were applied in block for 4 hr at room temperature, followed by 
three washes in PBS (1 hr / wash).  Devices were imaged on a   confocal microscope (Olympus 
Fluoview FV1000, Olympus America Inc., Center Valley, PA) using a 5x air or 40x water objective 
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then lightfield corrected [121]. 
 
3.2.5  Immunohistological tissue analyses 
 Prior to sectioning, photographs were taken of the cortical surface of whole perfused 
brains.  Serial sections were processed using indirect immunohistochemistry for CD68 (ED-1, 
AbD Serotec, Raleigh, NC, 0.25 μg/mL) to assess activated microglia/macrophages; IBA1 
(WAKO, Richmond, VA, 0.5 μg/mL) for microglial morphology and spatial distribution; GFAP 
(DAKO, Carpinteria, CA, 2.9 μg/mL) for astrocytes; NeuN (Chemicon/Millipore, Billerica, MA, 2.0 
μg/mL) for neuronal nuclei; MAP-2 (AP20, Chemicon/Millipore, 1.0 μg/mL) for dendrites; NF200 
(Sigma, St. Louis, MO, 8.0 μg/mL) for axons; RIP (NS-1, Chemicon/Millipore, 0.25 μg/mL) for 
myelination; rat IgG (Southern Biotech, Birmingham, AL, 0.5 μg/mL) for serum proteins in the 
brain parenchyma; and Lycopersicon Esculentum (Tomato) Lectin (Vector Laboratories, 
Burlingame, CA, 4.0 μg/mL), which labels vasculature and macrophages [72, 136, 190].  The 
same blocking solution used for explant analysis was used to dilute antibodies for tissue analysis.  
Free-floating (0.5 mL solution in 24-well plates) tissue sections were batch treated for 1 hr in 
blocking solution at room temperature, followed by incubation with primary antibodies for 18 hr at 
room temperature.  After three washes in PBS at room temperature to remove excess antibody (1 
hr / wash), appropriate fluorescently labeled secondary antibodies were applied in block for 18 hr 
at room temperature, followed by three washes in PBS (1 hr / wash).  All sections were also 
counterstained with DAPI (4',6-Diamidino-2-Phenylindole, Dihydroch loride, Life Technologies, 
Carlsbad, CA, 10 μM) to identify cell nuclei.  Tissue sections were mounted on microscope slides 
with Fluormount-G (Southern Biotech, Birmingham, AL) and cover-slipped.  Fluorescent images 
of tissue sections from the cortex were imaged on a confocal microscope using a 20x air 
objective, lightfield corrected, then stitched together in Photoshop to create a larger field of view 
[72].  Select sections were analyzed on a phase contrast microscope (Nikon Eclipse E600) using 








3.3  Results 
 
3.3.1  Retrieved device components were covered with adherent phagocytic macrophages 
 A representative MEA recording headstage and bone screw are shown in Fig. 3.1.  Under 
light microscopy retrieved device components, headstage adhesive and screws, contained an 
adherent layer of material of cellular origin indicated by DAPI+ staining of cell nuclei.  The 
adherent cells were almost exclusively immunopositive for CD68 and IBA1 (Fig. 3.2 and Fig. 3.3), 
indicating that they were activated macrophages.  A large difference in skull thickness was 
observed between young (10 weeks old, 325 g) and older (75 weeks old, 850 g) adult rats in the 
bone located above the motor cortex.  The younger adult rodent’s skull measured 560 μm and 
the older adult rodent’s skull measured 1170 μm.  In all animals the area of skull identified as the 
temporal ridge, which is prominent in laboratory rats, was observed as the thickest area of skull 
suitable for screw fixation. 
 
3.3.2  The foreign body response to screws in adjacent cortical tissue 
3.3.2.1  Macroscopic analysis and correlation of response to screw position 
 Every animal (n = 38) exhibited at least one area of the cortex, which showed a response 
associated with an implanted screw (Fig. 3.4A).  These cortical surface responses were visible in 
the perfused whole brain without magnification (Fig. 3.4).  The response was noticeable 
underneath 98 of the 114 (86%) screws and was circular and often concave in appearance.  
Unlike the rest of the perfused brain, the cortical surface underneath screws was darker and 
brownish in color, presumably due to blood products that were not cleared following perfusion 
and fixation.  These darker areas were evident over the entire indwelling period.  Following tissue 
processing and sectioning, light microscopy confirmed that these areas were associated with 
hemosiderin-laden macrophages and inflammation associated angiogenesis (data not shown).  
Regardless of headstage type, screw type, or animal age there was no apparent difference in the 








3.3.2.2  Analysis of cortical tissue response 
 Horizontal and coronal tissue sections showed increased CD68+ and IBA1+ 
immunoreactivity in cortical tissue underneath bone screws (Fig. 3.5B-C and 3.6B-C).  CD68+ 
macrophages adjacent to the interface had an amoeboid morphology, as compared to tissue 
further away.  Surrounding the area of CD68+ / IBA1+ cells was an enhanced immunolabeling of 
GFAP (Fig. 3.6E).  Coronal sections showed that increased GFAP immunolabeling could extend, 
in some cases, through the entire depth of the cortex (Fig. 3.6A).  Sections immunolabeled for 
IgG showed a gradient of intensity that declined as a function of distance from the center of mass 
of the adjacent screw (Fig. 3.5B-C and 3.6C).  Immunolabeled horizontal sections showed loss of 
neural tissue, which included a loss of neuronal nuclei (NeuN) and disruption of neural 
architecture (MAP-2, NF200 and RIP) (Fig. 3.7).  Immunolabeling with Tomato Lectin (TL) 
showed a disrupted vascular network, associated with the area of neural tissue loss (data not 
shown). 
 
3.4  Discussion 
 
 The results of this study show that various components commonly used to anchor 
recording and other biomedical devices to the rat skull for basic neuroscience and preclinical 
translational studies result in a FBR in adjacent brain tissue.  These components are collectively 
referred to as the headstage.  Results showed that any component, below the rat skull, was 
covered with a layer of CD68+ / IBA1+ macrophages.  This included the adhesives and cements, 
regardless of whether they were fabricated in situ or precast prior to implantation, as well as bone 
screws, irrespective of their design.  Furthermore, bone screws that penetrated the skull resulted 
in a FBR in the underlying cortical tissue, which had all of the FBR hallmarks as described for 
MEAs implanted in cortical tissue regardless of the depth of penetration. 
 Persistent macrophage activation was similar to that observed adjacent to penetrating 
cortical MEAs with the largest amount of CD68+ immunoreactivity residing immediately 
underneath the screw that was distributed in a pattern that reflected the overlying device 
geometry [76].  The extent of astrogliosis also appeared similar in spatial distribution and intensity 
to previous reports for penetrating MEAs, where astrocyte hypertrophy surrounded areas of 
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CD68+ immunoreactivity [73, 273, 274].  Similar to previous studies on penetrating MEAs, there 
were cells located within the area of the FBR that were DAPI+ but did not possess either 
macrophage or astrocyte biomarkers [73, 163].  Due to the proximity of the screws to meningeal 
tissue, it is plausible that these cells were meningeal fibroblasts, which may contribute to device 
encapsulation through extracellular matrix deposition [72, 75, 275].  Alternatively, they may have 
been neural progenitors attracted by soluble factor secretion from the activated macrophages 
[276]. 
 Evidence of larger scale neuroinflammation and neural tissue loss including elimination of 
neuronal cell bodies, processes, and myelination were also observed [76].  The response was 
similar to that described after focal brain injury or in multiple sclerosis, which have been shown to 
disrupt neuronal circuitry and lead to neural damage of varying scale [230, 277, 278].  These 
focal areas of neuroinflammatory-related damage were generally circular in appearance as 
viewed in horizontal sections and varied in both size and depth.  It is possible they resulted either 
from the initial injury associated with the drilling of pilot holes or screw insertion.  However, the 
presence of macrophages and inflammatory biomarkers weeks to months after screw insertion 
suggests that at least part of the observed response was due to the FBR associated 
neuroinflammatory sequela, as its resolution would have been expected if it was only associated 
with the initial injury [230, 277]. 
 We also observed BBB leakiness, which appeared as a gradient of IgG immunoreactivity 
that dissipated with increasing distance from the screw center of mass [124, 125, 279-281].  It is 
important to note that the figures provided in this study generally only show the tissue response to 
a single screw.  However, the collective inflammatory response to multiple screws and the other 
headstage components likely added to the neuroinflammatory burden of the implanted MEA, and 
may influence recording performance and/or brain function at sites other than the site of the 
penetrating MEA. 
 These results strongly suggest that headstage components are contributing factors to the 
overall neuroinflammatory burden of chronic recording devices, or other skull affixed biomedical 
devices, which has implications for mental health beyond the electrode-brain tissue interface.  
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This idea is supported by a broader set of studies that show the negative impact of regional and 
systemic inflammation on neurogenesis and cognitive function. 
 For example, it has been shown that proinflammatory cytokines released from 
macrophages can have neurophysiological effects at sites distant from the site of their release 
[282].  In a recent study, autoradiography was used to map macrophage and glial activation in the 
rat brain accompanying a deep brain stimulator (DBS) fixed to the skull with multiple screws and 
acrylic dental cement.  The results showed widespread and persistent neuroinflammation over an 
8-week indwelling period that was accompanied by cognitive deficits, as determined by an object 
recognition test [203].  
 Direct comparisons may be made with the contralateral hemisphere, which is a common 
imaging control for background and normal tissue immunofluorescent intensity in CNS studies 
[59-61, 68, 76, 86, 141, 144, 151, 178, 192, 214, 283-288].  A more stringent control would use 
sections from age-matched uninjured rat brains to establish the innate biomarker distribution in 
the utilized model system.  Some important anatomical features that are typically labelled by the 
biomarker panel at a heightened intensity in uninjured tissue include the glia limitans (GFAP, IgG) 
at the cortical surface, the corpus callosum where white matter tracts cross the midline (GFAP), 
and poorly perfused vasculature (IgG) [89, 289-291].  The IHC quantification process uses 
sections from the cortical regions V and VI as they are the thickest layers and have a fairly 
uniform cellular distribution [292]. 
 Other groups have established the connection between inflammation, neurogenesis, and 
changes in cognition.  One group employed a cortically-implanted electrode and cannula to 
directly stimulate neuroinflammation via lipopolysaccharide (LPS) infusion, and showed that the 
treatment decreased hippocampal neurogenesis [208].  Moreover, other groups have shown that 
inflammatory stimulation outside the CNS has detrimental effects on neurogenesis [207, 209, 
210] as well as on neural connectivity [211].  Together such studies support the notion that 
inflammation either located within the brain or systemically can impact neurogenesis and impair 
cognition. 
 In support of this work’s findings and their importance to larger and more clinically 
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relevant animal models, a recent publication identified headstage failure as a concern in 
nonhuman primate models, an experimental approach, which utilizes higher quality titanium 
mounts and bone screws in an animal that has a thicker skull [49].  In the current study, screw 
penetration depth was not controlled.  A review of the literature suggests that this is a variable 
that is not specifically controlled by any means in any study.  Moreover, screws are often used as 
electrical grounds or reference points for implanted recording devices, in which case they are 
intentionally implanted in cortical tissue [60].  Regardless of penetration depth, a high percentage 
of the screws used in this study (86%) elicited a FBR response in cortical tissue that resulted in 
loss of neural tissue and persistent inflammation.  Together, the results indicate that headstage 
components, especially bone screws, can contribute to the overall neuroinflammatory burden of 
biomedical devices that are anchored to the skull. 
 One suggestion for improved fixation would be the use of older adult rats that have 
thicker skulls, which facilitates better screw fixation.  A difference in skull thickness was observed 
across the two age groups with the skull thickness varying from 560 μm for the younger cohort of 
adult rodents to 1170 μm for the older animals, which is supported by the published results of an 
earlier study [293].  The thread spacing or pitch of a commonly used self-tapping bone screw for 
MEA headstage fixation measures approximately 400 μm (Fig. 3.8A).  If placed perpendicular to 
the skull bone of a young, 325g adult rat, only 1.4 screw threads would interface with the bone 
(Fig. 3.8B).  In contrast, 2.9 screw threads would interface with the bone of an older adult rat skull 
if placed in the same manner (Fig. 3.8C).  The common self-tapping bone screw has a tapered 
tip, which measures approximately 580 μm in length that does not provide any anchorage benefit.  
Thus, when used in either case it is impossible to obtain adequate fixation without the bone screw 
tip penetrating beneath the skull bone if the screw is placed in the flat part of the skull (Fig. 3.8B-
C).  An additional concern for headstage fixation is the consequence of skull growth and 
expansion resulting from normal development during chronic studies.  This issue is similar to 
clinical concerns regarding the use of metal plates for pediatric craniofacial surgery [294]. 
 Another suggestion for improvement is to ensure that the screws are located in the 
temporal ridge, the thickest area of the skull, and placed at an angle as shown in Fig. 3.8D.  The 
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temporal ridges are a prominent feature on the margins of the rat skull, which may facilitate better 
fixation and bury the tapered tip inside the skull bone, thus limiting contact with cortical tissue 
[295, 296]. 
 The broader impact of these findings can be extended to a number of other implantable 
research tools and medical devices for CNS applications.  These include not only neural 
recording devices, but deep brain stimulators, hydrocephalic shunts, optogenetic fiber optic 
probes, microdialysis probes, push-pull cannulas, tubing for drug infusion, and cranial windows 
used in advanced microscopy studies.  Many of these approaches rely on screws and adhesives 
to anchor such devices to the skull [198].  These results suggest that innovative approaches for 
device fixation to the skull could be broadly beneficial to several research and medical fields. 
 
3.5  Conclusions 
 
 Through an immunohistological analysis of headstage components and adjacent cortical 
tissue from 38 implanted rats, it was found that headstage components used to anchor neural 
recording devices elicit a FBR in adjacent brain tissue, characterized by neural tissue loss, 
persistent inflammation, astrogliosis, and BBB leakinesss, which adds to the neuroinflammatory 
burden beyond the electrode-brain tissue interface.  The broader impact of such device related 
persistent neuroinflammation is a possible influence on neural plasticity, neurogenesis, and 
cognition that should be considered as the use of these devices is contemplated for clinical 
application.  Future neural interface designs would benefit from a more holistic perspective that 
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Fig. 3.1.  MEA headstage and self-tapping fixation screw skull penetration.  (A) 16 channel 
Omnetics wired UEA anchored to the skull with an in situ fabricated headstage for chronic 
neural recording.  (B) Top view on headstage with bone screws visible through the 
polymer headstage used to anchor the implant and encapsulate the electrical connector 
and wires.  (C) Underside and top view (inset) of a bone screw implanted in the skull along 
the temporal ridge.  The conically shaped screw tip generally penetrates the skull as the 
threads do not begin until the screw diameter becomes constant, as seen in the inset.  




Fig. 3.2.  Immunohistological surface analysis of blunt machine screw showed that all 
implanted surfaces were covered in (A) a layer of biological material that was (B) 




Fig. 3.3.  Explanted device immunohistological surface analysis.  Representative in situ 
fabricated headstage used for chronic neural recordings.  (A) Top view on headstage with 
bone screws visible through the polymer headstage used to anchor the implant and 
encapsulate the electrical connector and wires.  (B) Underside and top view (inset) of a 
bone screw implanted in the skull along the temporal ridge.  The conically shaped screw 
tip generally penetrates the skull as the threads do not begin until the scre0w diameter 





Fig. 3.4.  Macroscopic remodeling (circled) of the cortex adjacent to fixation screws.  
These areas were crater-like in appearance and mimic the screw tip geometry.  The 
occurrence of macroscopic remodeling was equally associated with self-tapping and blunt 




Fig. 3.5  Immunolabeling of inflammatory biomarkers in cortical tissue adjacent to screw 
location (coronal plane).  Representative images of cortical tissue response 12 weeks after 
implantation.  (A) Surface view of perfused rat brain showing two screw locations (white 
arrows) and the sectioning plane (dashed line) of the tissue section shown in (B) and (C), 
which shows immunoreactivity against IgG (serum proteins; blue) showing BBB leakiness, 
CD68+ immunoreactivity (green) showing activated macrophages, and IBA1+ (red) 
showing macrophages.  (C) Magnified area in left hemisphere of B indicated with an 
asterisk showing magnified IgG immunoreactivity and activated macrophages (CD68+ / 
IBA1+) where the screw penetrated the skull.  (D) Magnified area in right hemisphere of B 
showing absence of CD68 immunoreactivity in the contralateral hemisphere equidistance 




Fig. 3.6.  Astrogliosis in cortical tissue adjacent to screw location (coronal plane) and 
upregulation of inflammatory biomarkers (horizontal plane).  Representative sections 
showing FBR biomarker distribution under a bone screw 12 weeks after implantation.  (A) 
A coronal tissue section taken adjacent to the section indicated in Fig. 3 showing 
increased GFAP+ immunoreactivity in the cortical column under the center of a bone 
screw in the left hemisphere.  Note the absence of GFAP in the contralateral hemisphere 
indicating that the reactivity dissipates as one moves away from the inflammatory 
stimulus.  Scale bar is 500 μm.  (Lower panels) Representative horizontal sections in 
cortex approximately at level indicated by dashed line in A showing the distribution of 
FBR biomarkers adjacent to a bone screw 12 weeks after implantation.  In all sections (B-
E), one can observe a circular area of neural tissue loss.  At the margin of the cavity there 
is an increase in IBA1+ immunoreactivity (B, green) that overlaps with a region of CD68+ 
immunoreactivity (C, red) and IgG+ immunoreactivity (C, blue) indicating the relationship 
between persistent inflammation and BBB leakiness.  At the margin of tissue loss and 
surrounding the activated macrophages was an area of enhanced GFAP+ 
immunoreactivity (D, green) indicating glial scar formation in the underlying cortex.  Scale 




Fig. 3.7.  Loss of cytoarchitectural and neurovascular networks (NeuN, NF200, RIP and TL) 
in cortical tissue adjacent to screw positon (horizontal).  Representative immunolabeling 
of various cellular and molecular FBR biomarkers adjacent to a bone screw 12 weeks after 
implantation.  Within the area of tissue loss there is an elimination of E) NeuN+ bodies, F-
G) NF200+/RIP+ myelinated axons, and H) TL+ vasculature.  TL also stains macrophages, 





Fig. 3.8.  Scaled drawing of a self-tapping bone screw penetrating the skull of young (10 
week old) and aged (75 week old) adult rats.  Screw dimensions which may influence 
fixation and the amount of screw penetration include the major diameter (Ø), pitch, taper 
length, screw angle and location.  An additional factor is skull thickness, which is 
influenced by age and location.  The thickness of the young adult rat skull (outlined in 
black, 560 μm) is less than half of the older adult rat skull (outlined in red, 1170 μm), based 
on craniotomy measurements.  The thickest area of skull suitable for screw fixation is the 
temporal ridge, a prominent anatomical feature found in laboratory rats, regardless of age.  






CONCLUSIONS AND FUTURE WORK 
 
 
4.1  Conclusions 
 
 The list below encompass the conclusions from this dissertation in its entirety and lays 
the foundation for the future directions and approaches addressed in section 4.2. 
 
4.1.1  ECM protein coatings 
 We hypothesized that ECM coatings which target initial hemorrhage should decrease 
aspects of the FBR by limiting the amount of hemorrhage, which is the initial trigger for 
inflammation and is neurotoxic. 
 Collectively, the results in Chapter 2 show that ECM coatings with different genetic 
backgrounds and compositions are able to differentially affect specific aspects of the FBR 
surrounding single-shank, silicon MEAs. 
 Silicon MEAs were coated with ECM through an adsorption dip-coating technique with 
either xenogeneic Avitene Microfibrillar Collagen Hemostat or allogeneic astrocyte ECM 
derived from an in vitro process. 
 In vitro hemostatic assays showed that the Avitene and astrocyte-derived ECM were both 
equally able to promote coagulation.  Furthermore, in vitro immunomodulatory assays 
showed that only the astrocyte-derived ECM coating had an influence on microglia 
phenotype, when compared to bare glass. 
 Using GFAP as an indicator, the astrocyte-derived ECM coatings decreased the degree 
of astrogliosis within the recording zone as compared to uncoated controls.  Conversely, 
there was no difference in GFAP surrounding the Avitene coated MEAs and uncoated 
controls.  This differential is most likely due to an immunomodulatory influence given the 
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equivalent hemostatic ability of both xenogenic Avitene and the allogeneic astrocyte-
derived ECM. 
 Using IgG as an indicator, the Avitene coated microelectrodes significantly increased the 
amount of blood products within the recording zone as compared to uncoated controls.  
This indicates a potential increase late phase neuroinflammatory sequela surrounding 
Avitene coated MEAs.  Conversely, there was no difference between the astrocyte-
derived ECM and uncoated controls. 
 Using CD68 and NeuN as indicators, neither the Avitene nor the astrocyte ECM coated 
microelectrodes had an influence on the intensity or spatial distribution of macrophage 
activation and neuronal density, respectively. 
 From these studies on ECM coatings there are a number of outstanding questions.  
Results showed that there was no beneficial influence of the hemostatic ECM coatings on CD68, 
IgG, and NeuN when using a single-shank MEA model, the most common for FBR studies.  
However, the influence of hemostatic ECM coatings on a different model system, such as a multi-
shank MEA, with larger amount of injury and initial vascular damage is unknown.  A surprising 
discovery was the increase in IgG adjacent to the Avitene coating.  This result raises questions 
about the fate of ECM coatings following 8 weeks in vivo.  In section 2.4 it was discussed that the 
existence of these coatings at 8 weeks would be unlikely, but the ultimate fate of the ECM 
coatings is unknown and worthy of future investigation.  One remaining question about the 
astrocyte-derived ECM coating is the decrease in GFAP, which may have been promoted by 
modulated macrophage activation.  However, it is unknown if this difference is attributed to 
allogeneic nature, tissue-specificity, cell-specificity, or derivation process used for the ECM 
harvest.  Finally, while the focus of this work was centered on biomaterial development and the 
FBR, for this work to influence the clinical translation of recording MEAs the influence on 
recording ability would need to be assessed.  Based on the results, a cell-derived ECM coating 







4.1.2  FBR to headstage components 
 We found that the FBR to fixation screws and fixation anchoring adhesive illicit a chronic 
FBR that has all of the hallmarks described for MEAs implanted in brain tissue. 
 Screws which penetrated the cranium could elicit increases in astrogliosis throughout the 
depth of the cerebral cortex.  This increase in GFAP is evident when compared with the 
contralateral hemisphere. 
 We found evidence of persistent neuroinflammation below a variety of fixation screws 
including chronic macrophage activation, demyelination, and neural tissue loss.  Both 
self-tapping and blunt machine screws exhibited this reaction. 
 The FBR of fixation techniques, which is common to a wide variety of CNS devices, may 
improve the biocompatibility of existing devices and provide a reference for future 
biologically-informed device designs. 
 From these studies on the headstage FBR there are a number of outstanding questions.  
Based on studies in the literature a relationship can be developed between the FBR and the 
widespread neuroinflammatory burden.  However, a direct correlation of IHC biomarkers and 
autoradiography markers, such as PK11195, or other indicators of systemic inflammation may be 
useful for directing the biomaterials and device design fields.  From a design perspective a 
strategy such as decreasing the surface area of the headstage may lower its neuroinflammatory 
burden, but a comprehensive design and evaluation process that identifies and tests strategies to 
maximize device fixation while minimizing the neuroinflammatory burden is lacking in the 
literature.  For proper evaluation, both of these outstanding questions would most likely require a 
dedicated study that allows for exclusion of the cortically implanted device and a sole focus on 
headstage development. 
 
4.2  Future Directions and Approaches 
 
 A number of future directions and approaches can be based on the results and 
conclusions presented in this dissertation.  Sections 4.2.1-4.2.6 focus on the ECM coatings 




4.2.1  In vitro mechanistic studies of ECM coatings 
 The first rational direction to develop a better understanding of the ECM coatings 
influence on the FBR is through in vitro mechanistic studies.  These studies would provide 
insights on specific cellular interactions with the ECM coated interfaces in a controlled in vitro 
setting. 
 To advance knowledge on the hemostatic potential of ECM a number of strategies could 
be used to better understand platelet interactions as they are an important moderator of 
coagulation.  One of the most powerful techniques is parallel plate perfusion, which allows for the 
perfusion of whole blood or platelet rich plasma at a controlled perfusion speed and associated 
shear force.  The level of shear may prove important for future studies given the composition of 
the astrocyte-derived ECM, which contained collagen type VI and type XII.  These collagen types 
facilitate platelet adhesion at low shear rates, but not high shear rates.  Conversely, collagen type 
I-III are able to facilitate platelet adhesion and activation at higher shear rates [180].  A potential 
experimental design for a first study on platelet interactions would be to flow platelet rich plasma 
over uncoated controls, Avitene coated, and astrocyte-derived ECM coated with a range of shear 
rates (i.e., 300, 800, and 2000 s-1) [182, 297].  The dynamic platelet interactions with the surface 
may be viewed in real-time with differential interference contrast microscopy or post processed 
with Giemsa staining following glutaraldehyde fixation and methanol dehydration.  Other 
techniques to analyze platelet activation include the quantification of soluble factor release.  For 
example, adenosine triphosphate release is quantifiable through surface-immobilization of firefly 
luciferase or β-thromboglobulin release is quantifiable through an enzyme-linked immunosorbent 
assay (ELISA) [179, 298, 299]. 
 Results from Chapter 2 show that ECM coatings derived from astrocytes in vitro is able to 
modulate macrophage activation in vitro.  This result is based on a single test, additional assays 
which build on this and provide a better understanding of the ECM’s influence on inflammation 
may provide insights on the differential response seen in the GFAP (Fig. 2.7 and 2.8) and IgG 
(Fig. 2.9) results surrounding ECM coatings.  While the influence of the Avitene and astrocyte-
derived ECM coatings on macrophage phenotype in vitro was assessed, the macrophages’ 
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secretion profiles are unknown on these coatings.  The use of an ELISA or mass spectroscopy on 
macrophage secreted media and quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) on cell lysate would inform us on which proteins, cytokines, and chemokines are 
being secreted or genetically upregulated, respectively [121, 300].  Additionally, derivation of 
macrophages from other tissue sources, such as bone marrow, may prove useful for comparative 
analysis with our previous results on microglia harvested from rat pup cerebral cortices.  Findings 
from this comparison would contribute to the growing body of research seeking to understand 
microglia’s role in the CNS injury [102, 103, 301]. 
 
4.2.2  In Vivo mechanistic studies of ECM coatings 
 The second rational path to direct the understanding of the ECM protein coatings is in 
vivo mechanistic studies.  These studies would build on knowledge acquired during the in vitro 
studies and the in vivo results from Chapter 2 to provide insights on the ECM coatings influence 
on the acute tissue response and the longevity of the ECM coatings. 
 Shorter time points would be the first in vivo study to build on the results presented in this 
dissertation.  Two specific time points of interest would be 48 hr and 2 weeks.  These time points, 
especially 48 hr, are commonly used in the fields of TBI and stroke to assess hemorrhage 
formation, and thus would provide a better understanding of the ECM coatings in vivo hemostatic 
performance [302, 303].  Also, it is known from previous studies that the glial scar surrounding a 
similar device does not change after 2 weeks [73].  Therefore, analysis of inflammatory and 
astrocyte biomarkers surrounding astrocyte-derived ECM may answer if the decrease in GFAP at 
8 weeks is attributed to acute immunomodulation or a specific interaction with astrocytes. 
 A second in vivo study would be the prelabeling of coated proteins with a marker which 
can be later detected in tissue.  This could provide insights on the activity of surface adherent 
macrophages (Fig. 4.1) and possibly be used to track their migration following interaction with the 
device interface.  Care must be taken in this step to minimize the alterations to the protein 
function.  Potential labeling techniques would include fluorophore conjugation to the proteins, 
which would be the simplest through an amine-fluorophore conjugation with either the Avitene or 
the astrocyte-derived ECM coating.  This step could be integrated prior or during the coating 
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deposition.  However, fluorophores are hydrophobic which could have influence on the FBR as 
the adsorption of labelled proteins would be affected, thus requiring a fluorophore only coating for 
control [304].  A different labeling technique which has been previously used to assess ECM 
scaffold degradation would be the radiolabeling of the proteins [245].  An advantage of this 
technique is the limited influence on the natural ECM architecture.  One experimental approach 
involves supplementing the source animal with 14C-proline, which integrates within the native 
triple helix of fibrous collagen.  This would be unfeasible for ECMs where there is no control the 
development, such as Avitene, but may be possible for the cell-derived ECMs developed in vitro.  
A potential path for post developmental radiolabeling of ECM could use an amine conjugation to 
integrate the radiolabeled element [305, 306].  If radiolabeling is accomplished, the quantity of 
material in tissue sections could be quantified at various time points with liquid scintillation 
counting (LSC) [307, 308].  To better determine the spatial distribution it may be possible to 
isolate micrometer size regions of tissue with laser capture microdissection (LCM) [309].  LCM 
and radio-iodination have not been previously combined in this manner, but similar approaches 
indicate that labeled protein sensitivity would be adequate for quantification [310]. 
 Lastly, gene delivery techniques could enable a number of studies on in vivo 
mechanisms.  First, it could enable labeling of cells at the interface through viral transduction of 
GFP [311].  Along with these GFP, other genes encoding the knock-in of anti-inflammatory 
molecules or knockdown of proinflammatory molecules could be delivered [312, 313].  One 
example showed transduction of IL-10 in cells (mostly macrophages) surrounding an implanted 
polymer scaffold which decreased leukocyte trafficking by 50% relative to controls at 7 days post-
implantation [314].  This would be a powerful way to interrogate inflammation’s influence on the 
chronic FBR surrounding CNS implants.  One of the most important parts of this approach is to 
ensure efficient cellular transduction.  Techniques where delivery of the vector is rapid (e.g., 
injection) have experienced poor gene transduction.  However, prolonged delivery via 
immobilizing the viral vectors within a degradable substrate, such as PLGA, improves the efficacy 
of gene delivery [315].  For MEAs, this could be done by linking PLGA to the surface either as a 
coating or as an aggregate of nanoparticles.  While the translatable nature of genetic engineering 
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is uncertain, these techniques may allow the field to ask the next phase of questions that will 
improve clinical efficacy of CNS devices. 
 
4.2.3  Investigate new FBR biomarkers and quantification approaches 
 To better understand the FBR surrounding brain implanted devices, it may prove 
beneficial to expanded immunohistochemical quantification in the future with novel biomarkers, 
higher magnification quantification, and emerging techniques. 
 Various studies indicate a heterogeneity of macrophage phenotypes.  Within this dogma, 
macrophages have mostly been classified as M1 (proinflammatory) or M2 (proregenerative).  
However, it is well-recognized now that this view is incomplete as the phenotypes of 
macrophages in vivo are much more variable than the induced phenotypes observed in vitro due 
to supplementation of LPS and various interleukins [316, 317].  Still, these techniques have 
pushed the field to recognize new biomarkers for quantifying cell phenotype.  Two differential 
biomarkers that seem promising from these macrophage phenotypic studies are arginase and 
iNOS which may be detected through immunolabeling, similar to the protocols used in Chapters 2 
and 3 [190].  These two markers are promising because they originate from a diverging pathway 
which is based on competitive metabolization of the same substrate, L-arginine.  The products of 
iNOS metabolism of L-arginine are inflammation and tissue damage (NO and L-citrulline).  
Conversely, arginase metabolism of L-arginine results in ECM production and cell proliferation (L-
proline and polyamines) [317, 318]. 
 Laser capture microdissection of tissue could also be combined with qRT-PCR to map 
the genetic upregulation of various biomarkers surrounding the uncoated and ECM coated 
interfaces.  This could be a beneficial supplement to quantitative IHC used to describe the FBR.  
This technique has been used to profile sections from multiple intracortical MEA studies [120, 
124], which indicated an increase in various matrix metalloproteases (MMP), including 
gelatinases MMP-2 and MMP-9, which are potent drives of inflammation and are associated with 
BBB permeability [319].  Adoption of this approach may be especially useful for comparing the 
neuroinflammatory profile of the FBR surrounding uncoated controls and ECM coated MEAs.  
However, a number of pitfalls have been identified with qRT-PCR, including poor correlation 
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between mRNA and protein abundance, which should to be considered prior to technique 
adoption [320]. 
 
4.2.4  Influence ECM derivation process and cell/species origin of the ECM protein coatings 
 For the derivation of ECM in vitro an area of improvement is the design and need for 
sacrificial scaffolds.  An alternate scaffold fabrication technique, electrospinning of polymer 
nanofibers, would provide a higher degree of tortuosity within the scaffold than the porous PU 
scaffolds and may further promote the degree of molecular crowding and ECM accumulation (Fig. 
4.2A-B) [321].  However, a better route may be to eliminate the sacrificial scaffold all together.  
One means to do this would be electrospinning of a nanofiber protein scaffold, similar to those 
fabricated with solubilized collagen suspended in 1,1,1,3,3,3-hexafluoro-2-propanol [322, 323].  
This initial electrospun protein scaffold could then serve as the substrate and be enriched by in 
vitro cell proliferation and ECM accumulation.  Furthermore, it was shown in our lab that 
derivation of ECM is possible from decellularized cell sheets (Fig. 4.2C) [324].  These alternate 
cell-derived harvesting techniques may be useful for delineating what influence the harvesting 
technique has on differences observed surrounding the ECM coatings. 
 The results within Chapter 2 are the first FBR response to an allogeneic cell-type specific 
ECM coating, and indicate that ECM origin and composition have an influence on the FBR.  A 
next step is to use ECM proteins derived from different cellular origins or with more specific 
protein composition to delineate the role of cell-, tissue-, and species-specificity. 
 One advantage of the cell-derived ECM is that it originates from a specific cell type in a 
controlled environment.  This has proven useful for deriving ECM from cells of various potential 
such as mesenchymal stem cells and from different tissues such as the dermis [234, 236].  In 
relation to its influence on the FBR, it limits the ability to isolate the effect of a specific protein on 
the FBR.  Although, isolating a single protein for the coating would obscure the possibility that a 
heterogeneous protein composition may be required for the observed benefit or deficit.  Some 
single proteins that may prove useful, but have not been investigated in vivo, are biglycan, 
decorin, lumican, or homologous proteins, which have been shown to modulate TGFβ1 signaling 
and may have more influence on the FBR. 
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 A potentially interesting experiment would be the assessment of a proinflammatory 
protein coating, using proteins such as IL-1β, IL-6, MCP-1, or RANTES.  The inflammatory 
chemoattractant protein RANTES could be one option and has been investigated in vivo through 
subdermal injections and showed upregulation in the activation of eosinophils, mast cells, 
lymphocytes, macrophages, and basophils [325].  Given that attempts to decrease the chronic 
inflammation at the electrode-tissue interface have had limited influence, the rationale for this 
experiment would be to better understand the influence of acute inflammation on the other 
aspects of the FBR, and to ask if an increased acute inflammatory response leads to an elevated 
or equivalent chronic inflammatory response and FBR, when compared to uncoated controls.  
The approach for this experimental concept would most likely require analysis of several coatings 
with various concentrations of the proinflammatory stimulus to understand the thresholds of 
proinflammatory delivery. 
 
4.2.5  Determine ECM coating’s influence on a clinical device with an increased FBR 
 The model device for the presented work, a silicon single-shank MEA, was chosen based 
on its use historically to understand the FBR.  A potential path forward to address multiple facets 
of the FBR would include coating a lattice designed MEA as indicated in our previous work [163].  
Surrounding the lattice, there was a decrease in inflammation (CD68), BBB permeability (IgG), 
and an increase in neuronal density (NeuN).  However, the lattice architecture did not decrease 
the level of astrogliosis (GFAP).  The allogeneic astrocyte-derived ECM coating, on the other 
hand, was able to influence the level of astrogliosis while not having an influence on the other 
aspects of the FBR.  Thus, combining the lattice architecture and ECM coating may prove 
synergistic and minimize multiple aspects of the FBR (Fig. 4.3). 
 Yet, as indicated to in section 1.3.2, these single-shank silicon MEAs create a fairly small 
degree of damage in comparison to multi-shank MEAs, such as the UEA.  From one perspective, 
a multi-shank model may provide a different result as it is essentially increasing the signal-to-
noise ratio of the IHC quantification, with the signal being the level of biomarker immunoreactivity 
adjacent to the interface and the noise being the level in background tissue.  Furthermore, this 
larger injury is characterized by a prominent lesion and tissue loss occurring below the base (Fig 
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4.4).  This larger injury may originate from the loss of vasculature perfusion redundancy in the 
brain, which is relatively robust when a focal area of vascular is ruptured.  However, more 
widespread instances of damage may result in loss of this redundant vascular perfusion and a 
larger area of damage [35].  Thus, it is reasonable to believe that a hemostatic coating maybe 
have a different response in this model system due to increased biological interactions.  This 
larger injury has been quantified in terms of cavity volume as defined by a prismoidal formula and 
immunofluorescence of biomarkers within the first 100 μm of the outermost electrodes [27].  Due 
to the lesion this quantification approach, unlike the one used for single-shank MEAs, is unable to 
assess the reaction around each shank of the UEA due to the irregularities of the cavity.  Given 
that the only influence on the FBR was observed within 50 μm of the single-shank MEAs, it may 
be necessary to revise these previous quantification approaches to more specifically analyze the 
reaction to the individual electrode shanks. 
 
4.2.6  Incorporate recording techniques to assess functional correlations 
 Ultimately one of the most important future experiments for the presented work and any 
technique that alters the FBR is the integration of a functional assessment.  This could be done 
with a functionalized single-shank MEA.  However, given that the UEA is one of the most utilized 
recording devices, it would be logical to integrate recording into the section 4.2.5.  A majority of 
the recording data with UEAs originates from primates.  However, its adoption in rats may grow 
with use of smaller 4 x 4 UEAs as detailed in a recent report from our lab [68].  The metrics most 
often associated with recording performance are signal-to-noise ratio (how high is the recording 
signal compared to background noise), driven channels (how many electrode sites are able to 
detect single unit APs), electrode impedance (the ability of current to flow under a driving voltage, 
typically 1 kHz), and recording longevity (for what length of time are single unit APs detectable) 
[49, 58, 61, 68, 70, 326].  The experimental protocol for recording would follow similar studies 
[68], and employ a Cerebus or Cereplex recording data acquisition system supplied by Blackrock 
Technologies Inc. and equipped with Plexon Offline Sorter software to quantify the signal-to-noise 
ratio, driven channels, and recording longevity as described above.  Additionally, with the 
compatible Cereplex A amplifier the impedance of each electrode in the UEA can be quantified 
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and would add to the results from previous work which did not assess impedance.  Impedance 
has been suggested as a correlate to cell reactivity and astrogliosis surrounding the MEA 
interface, thus it is believed that the allogeneic astrocyte-derived ECM coating would improve this 
recording metric [327, 328]. 
 
4.2.7  Influence of headstage on systemic inflammation and neurogenesis 
 A few techniques which would be interesting to expand our understanding of the 
headstage FBR include the cytokine analysis from blood draws at acute and chronic time points, 
assessment of neurogenesis, cognitive function, and other techniques to assess 
neuroinflammation.  Ideally these experiments would be done with the headstage alone as a 
control.  One potential technique uses autoradiography of [3H]PK11195, which labels a 
benzodiazepine receptor, to quantify microglia and astrocyte reactivity [329].  One study which 
used this technique to show the neuroinflammatory burden of DBS implants in rats controlled for 
the influence of the surgery with a surgical sham, however, failed to assess the influence of the 
screws and dental acrylic used to affix the DBS to the skull by implanting only a headstage [203]. 
 Assessment of neurogenesis and cognitive ability could be performed in tandem with 
other techniques through hippocampal evaluation determined by the proportion of 
Bromodeoxyuridine-positive (BrdU+) proliferative cells that co-express the early neuronal marker 
doublecortin (Dcx) and an animal memory exercise such as object recognition test [207].  Using 
this technique with a number of different headstage designs, and the absence of an intracortical 
implant for control, it would be possible to better determine the neuroinflammatory burden of the 
headstage alone and guide the field on which approach might least influence brain health. 
 Incorporation of a device development and commercialization phases in a NIH 
SBIR/STTR or technology development grant (such as those distributed at the state level for 
technology commercialization) would strengthen the funding potential and ultimate impact of the 
work by providing for a more comprehensive analysis and development phases, with analyses 
from Chapter 3 partially serving as developmental design parameters.  In this way, understanding 
the FBR to headstage components plays into the larger issue of improved headstage 
components and improved surgical methods for small animal studies. 
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4.2.8  Design of universal small animal skull fixation device or technique 
 A purpose of Chapter 3 is to serve as a stepping stone for biologically-informed device 
design.  Design of a novel fixation techniques for rodents and other small animals would benefit a 
number of fields.  Some criteria that need to be considered for this new fixation technique are 
detailed below. 
 Fixation strength is a primary concern as any new methodology needs to ensure that it 
will not compromise the study.  Furthermore, it should endeavor to provide a level of 
fixation that decreases the fixation failures of current designs.  This strong fixation is 
needed to compensate for animals manipulation of transcutaneous components as well 
as their natural grooming patterns.  Headstage designs for larger animals use titanium 
components to promote osseointegration due to the titanium oxide-bone interactions 
[330].  The use of these materials have yet to translate to rodent CNS experiments as the 
common materials still used are stainless steel screws and dental acrylic. 
 Size and surface area of the headstage should be minimized without compromising 
anchorage.  Eliminating the screws and management of skull penetration is one of the 
largest challenges in regard to fixation.  Additionally, a new device or technique would 
need to account for the innate variability of skull shape and thickness within species, as 
well as interspecies (rat, mouse, guinea pig).  Since the skull size and shape changes 
over the lifespan of animals, another consideration would need to be the age of the 
animals at implant and the intended study length. 
 Modularity of the technique or headstage device would be needed for adoption by 
multiple fields.  In rodents the most common craniotomy location for access to the cranial 
vault is in the parietal plate, thus the design would need to maintain this area of 
accessibility. 
 Ease of use and cost would also play a large role in the adoption of the techniques or 
fixation device.  Most importantly the ease of use would help promote repeatable fixation 
and limit surgeon related variability. 
 From these criteria and considering the headstages used in larger animal models, the 
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most direct path forward would be a titanium plate and screw headstage designed for the rodent 
skull (Fig. 4.5 and 4.6).  An added benefit of titanium would be the possibility of sintering or 
creating pores on the baseplate surface (Fig. 4.5B) to further promote osseointegration.  Levering 
the osseointegration advantage may allow for a decrease in the screws required and the total 
implanted surface area.  Fabrication of such devices would be feasible within the laboratory 
setting through the use of laser etching techniques which could be used for developing the 
baseplate profile as well as creating the porous surface on the base of the plate.  Laser etching 
has shown an ability for high tolerance cutting of titanium within an inert gas environment [331], 
and studies indicate a laser textured pore size of 200 μm would be optimal for promoting 





Fig. 4.1.  Surface adherent macrophages on single-shank and multi-shank MEAs.  (A) 
Single-shank planar MEA under lightfield illumination.  Scale bar 50 μm.  (B-C) The same 
location on an explanted single-shank MEA showing a layer of activated macrophages 
(MAC-1+ / CD68+).  (D) Multi-shank MEA (16-channel UEA) under lightfield illumination.  
Zoom box indicates similar location from (E) an explanted MEA showing a layer of 
activated macrophages (IBA-1+ / CD68+). 
(A-C) Adapted by permission from Elsevier: Biomaterials, R. Biran, D. C. Martin, P. A. 
Tresco, Neuronal cell loss accompanies the brain tissue response to chronically implanted 
silicon microelectrode arrays, Exp. Neurol. 195 (2005) 115-126. 
http://dx.doi.org/10.1016/j.expneurol.2005.04.020. [76], Copyright 2005.  (D-E) Adapted by 
permission from Elsevier: Biomaterials, N. F. Nolta, M. B. Christensen, P. D. Crane, J. L. 
Skousen, P. A. Tresco, BBB leakage, astrogliosis, and tissue loss correlate with silicon 
microelectrode array recording performance, Biomaterials 53 (2015) 753-762. 




Fig. 4.2.  Electrospun polyurethane scaffolds and astrocyte-derived ECM cell sheet.  (A) An 
anisotropic PU scaffold deposited on a conductive spinning mandrel.  (B) A grid patterned 
PU scaffold deposited on a stationary conductive wire mesh.  (C) Decellularized astrocyte-
derived ECM sheet similar to those fabricated by Meng et al. [324].  The picture sheet 
(white arrow) retracted from the edge but remained adherent to the coverslip during 
detergent and enzymatic decellularization steps.  These sheets were robust enough to 
wrap a single-shank planar MEA.  However, the innate tension of the sheet caused the 




Fig. 4.3.  Single-shank lattice geometry silicon MEA coated with astrocyte-derived ECM.  
(A) Uncoated control lattice MEA compared with (B) an astrocyte-derived ECM coated 
MEA.  In previous studies the lattice geometry showed a lower level of inflammation and 
BBB permeability, however did not decrease the level of astrocyte reactivity [163].  
Combining this approach of device geometry modification and the ECM coating, may 




Fig. 4.4.  Lesion size at various cortical depths resulting from multi-shank MEA 
implantation.  Representative horizontal sections from an animal sacrificed at 4 weeks 
showing cell nuclei (DAPI, blue), axons (NF200, yellow), activated macrophages 
(CD68/IBA-1 colocalization, green), BBB leakage (IgG, red), and astrocyte cytoskeleton 
(GFAP, cyan).  Sections from three different depths are shown including -500 μm, -1000 
μm, and -1500 μm.  Hypercellular, CD68+, IBA-1+, IgG+, NF200- areas of damaged neural 
tissue were most evident superficial cortex(-500 μm), while microelectrodes apart from the 
tissue loss areas had an FBR typical of single-shank MEAs.  In deeper cortex (-1000 μm 
and -1500 μm), the tissue loss area was smaller.  Scale bar 500 μm. 
Reprinted by permission from Elsevier: Biomaterials, N. F. Nolta, M. B. Christensen, P. D. 
Crane, J. L. Skousen, P. A. Tresco, BBB leakage, astrogliosis, and tissue loss correlate 
with silicon microelectrode array recording performance, Biomaterials 53 (2015) 753-762. 





Fig. 4.5.  Theoretical titanium headstage mount for fixation of electrical connector in 
rodents.  (A) Top view of headstage securement design showing the integration of 
countersunk screw holes to minimize the vertical profile.  Inner edge has been designed to 
retain a single Omnetics electrical connector, however may be easily adapted to integrate 
a cannula or cranial window.  (B) Bottom view of possible design showing a porous 
titanium base to support osseointegration and mechanical interlocking with the skull 
bone, similar to protocols used for orthopedic devices [333].  Additionally, one of the most 
important aspects would be the screw in plate design which limits the potential skull 
penetration.  The proposed design has a 600 μm penetration limit, detailed in Fig. 4.6, 





Fig. 4.6.  Dimensions of theoretical titanium headstage mount pictured in Fig. 4.5.  CAD 
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